WO2005000265A2 - Gel-stabilized nanoparticulate active agent compositions - Google Patents

Gel-stabilized nanoparticulate active agent compositions Download PDF

Info

Publication number
WO2005000265A2
WO2005000265A2 PCT/US2003/028380 US0328380W WO2005000265A2 WO 2005000265 A2 WO2005000265 A2 WO 2005000265A2 US 0328380 W US0328380 W US 0328380W WO 2005000265 A2 WO2005000265 A2 WO 2005000265A2
Authority
WO
WIPO (PCT)
Prior art keywords
less
active agent
composition
gelatin
nanoparticulate
Prior art date
Application number
PCT/US2003/028380
Other languages
French (fr)
Other versions
WO2005000265A3 (en
Inventor
Simon L. Mcgurk
David A. Czekai
Original Assignee
Elan Pharma International Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma International Ltd. filed Critical Elan Pharma International Ltd.
Priority to DK03816299.6T priority Critical patent/DK1553927T3/en
Priority to SI200331901T priority patent/SI1553927T1/en
Priority to AT03816299T priority patent/ATE487470T1/en
Priority to EP03816299A priority patent/EP1553927B9/en
Priority to DE60334924T priority patent/DE60334924D1/en
Priority to JP2005503259A priority patent/JP4878839B2/en
Priority to AU2003304237A priority patent/AU2003304237A1/en
Priority to CA2498207A priority patent/CA2498207C/en
Publication of WO2005000265A2 publication Critical patent/WO2005000265A2/en
Publication of WO2005000265A3 publication Critical patent/WO2005000265A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Definitions

  • the present invention relates to a solid or semi-solid gelatin dosage formulation comprising a nanoparticulate active agent.
  • the nanoparticulate active agent Prior to incorporation in the dosage form, the nanoparticulate active agent preferably has an effective average particle size of less than about 2 microns.
  • Nanoparticulate active agent compositions first described in U.S. Patent No.
  • Nanoparticulate compositions are desirable because with a decrease in particle size, and a consequent increase in surface area, a composition is rapidly dissolved and absorbed following administration.
  • Methods of making nanoparticulate active agent ' compositions are described, for example, in U.S. Patent Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No.
  • Nanoparticulate active agent compositions are also described, for example, in U.S. Patent Nos.
  • Drug products are currently designed for three groups of individuals: infants, pediatrics, and adults.
  • the needs of infants are different from those of children 2 to 12 years of age, and the needs of children are different from those of adults.
  • the needs of the elderly population are different than those of other adults.
  • Another category of individuals needing an alternative drug delivery form are patients with chronic dosage regimens. Repeated dosing of tablets or pills may become problematic for patients having a need for daily dosage regimens. Thus, an alternative dosage form is needed for a variety of patient populations.
  • Pediatric patients have difficulty swallowing until they reach the age of about
  • Liquid dosage forms are relatively easy to administer but are more costly, easily spilled, often do not taste good, occupy large volumes of space per dosage unit, and possess stability problems. [0010] As is evident, the needs of the elderly differ from those of other populations and deserve special attention in new drug development, product formulation, product packaging, product labeling, patient information, and product marketing and sales. A practical and new dosage form would be of value for these patients as well as others.
  • a gelatm drug delivery system would be beneficial in achieving ease of administration in both young, older, and chronic dosage patients. However, such a dosage system must exhibit sufficient stability and bioavailability. Without sufficient bioavailability and active agent stability, ease of administration is just a single step in the process of pharmaceutical therapy. Prior art gelatin dosage forms have been unable to solve this dual necessity of bioavailability in combination with active agent stability.
  • the most typical gelatin drug delivery formulations comprise gelatin coated tablet formulations and gelatin encapsulated solid cores or liquid cores of pharmaceutical agents.
  • One such example is found in U.S. Patent No.
  • a soft gelatin capsule comprising a suspension of a solid phase in a liquid phase, with the solid phase consisting of encapsulated beads having a mean diameter of from about 149 ⁇ m to 2500 ⁇ m.
  • the beads comprise a coating effective to prevent interaction of the active agent with the liquid phase or the soft gelatin capsule.
  • Tanner et al. fail to disclose a solid or semi-solid gelatin formulation.
  • An example of a gelatin dosage form has been disclosed by Wunderlich in
  • U.S. Patent No. 5,932,245 (“the '245 patent”).
  • This patent is directed to a dosage formulation that provides: (a) an inner phase comprising at least one nanoparticle compound having an average size ranging from 10 to 800 nanometers; and (b) an outer phase comprising gelatin, collagen hydrolyzates, or mixtures thereof.
  • the inner phase of this composition is negatively charged and the outer phase is positively charged when the dosage formulation is dissolved in an aqueous solution having a pH of less than 9.5, or the inner phase is positively charged and the outer phase is negatively charged when the dosage formulation is dissolved in an aqueous solution having a pH of higher than 3.5.
  • This reference differs from the present invention in several aspects.
  • the '245 patent requires solubilization of the active agent as part of the process of making the described nanosol compositions.
  • the solubilization is achieved either through the use of a solvent (col. 17, lines 30-34), followed by evaporation of the solvent, or through modification of the pH of the gelatin.
  • a solvent col. 17, lines 30-34
  • an active agent is dissolved in ethanol, isopropanol, methanol, or acetone (col. 18, lines 32-36; col. 20, lines 18-20 and 44-48; col. 22, lines 4-5 and 29; col. 23, lines 30-32) or the active agent is dissolved in the gelatin via modifying the pH of the gelatin (col. 18, lines 52-55; col. 21, lines 23-28 and 43-50; col. 22, lines 61-67).
  • solubilization of an active agent is undesirable, as solubilization affects the various properties of the active agent, such as the solidification state of the active agent (i.e., whether the active agent is in an amorphous or crystalline form), stability of the active agent in the aqueous state, how much of the active agent has returned to the solid state, etc.
  • solubilization is required because in the compositions of the '245 patent, the gelatin functions to stabilize the nanoparticles of the active agent, as pictured below:
  • gelatin composition "surround and stabilize" the active agent in the composition of the '245 patent is to first solubilize the active agent in the gelatin, or in a solvent followed by mixing the solvent/active agent solution with the gelatin solution and subsequent evaporation of the solvent.
  • This is in contrast to traditional nanoparticulate drugs, which do not require solubilization of the active agent. Rather, such compositions utilize a surface stabilizer, such as a surfactant, to stabilize the nanoparticulate size of the active agent following particle size reduction via, for example, milling or homogenization. See e.g., U.S. Patent No.
  • ibuprofen having a particle size of from 10 to 800 nanometers, in the form of a nanosol.
  • the '332 patent requires solubilization of ibuprofen to make the described gelatin formulations. See e.g., col. 8, line 60, through col. 9, line 5; col. 9, lines 15-16 and 31-34.
  • the ibuprofen is dissolved in a solvent such as ethanol, isopropanol, methanol, or acetone (col. 8, lines 60-62; col. 9, lines 31-34; col.
  • This patent is directed to a rapidly dissolving pharmaceutical dosage form produced by combining a particulate support matrix with a pharmaceutical ingredient to form a dosage mixture, followed by forming the dosage mixture into a dosage form.
  • the dosage form When introduced into an aqueous environment, the dosage form is substantially completely disintegrable within less than about 20 seconds.
  • the particulate support matrix is formed by providing an aqueous composition comprising: (a) an aqueous medium, (b) a support agent comprising a non-hydro lyzed gelatin component having a predetermined net charge, (c) a hydrolyzed gelatin component having a predetermined net charge of the same sign as the non- hydrolyzed gelatin component, (d) a bulking agent, and (e) a volatilizing agent.
  • the hydrolyzed gelatin component has a solubility in aqueous solution greater than that of the non-hydrolyzed component.
  • the aqueous composition is introduced as droplets into a drying chamber heated to a temperature sufficient to cause evaporation of substantially all of the aqueous medium and volatilizing agent from the droplets leaving the support agent in a dried particulate form comprising the particulate support matrix.
  • This formulation fails to retain excess water, which is essential for effective redispersabihty, and hence the Allen et al. formulation exhibits poor pharmaceutical bioavailability.
  • the new dosage forms comprise a gel-forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gel.
  • the gelatin solid or semi-solid dose formulations of nanoparticulate active agent compositions comprise at least one nanoparticulate active agent having an effective average particle size of less than about 2000 nm, and at least one surface stabilizer adsorbed on or associated with the surface thereof.
  • the active agent can be poorly soluble in at least one liquid media, such as water.
  • the gelatin solid or semi-solid dose nanoparticulate active agent formulations comprise at least one gel forming substance, which provides an active agent dosage form having ease of administration, improved stability of the active agent, and improved dissolution.
  • the gelatm solid or semi-solid dose formulation also exhibits increased redispersion of the component active agent, which achieves pharmaceutically acceptable bioavailability.
  • compositions comprising a nanoparticulate active agent composition of the invention.
  • the pharmaceutical compositions preferably comprise at least one active agent, at least one surface stabilizer, at least one gel forming substance, and at least one pharmaceutically acceptable carrier, as well as any desired excipients.
  • a method of preparing gelatin nanoparticulate solid or semi-solid dose formulations comprises: (1) forming a nanoparticulate active agent composition comprising at least one active agent and at least one surface stabilizer; (2) mixing the nanoparticulate active agent composition with melted gelatin, and (3) forming a solid dose form of the composition for administration. The method does not comprise solubilizing the active agent.
  • Yet another aspect of the present invention provides a method of treating a subject, including a human, comprising admimstering a solid or semi-solid gelatin nanoparticulate active agent formulation of the invention, wherein the gelatin formulation exhibits gelation sufficient to retain excess water.
  • Figure 1 Shows the blood levels of ketoprofen over a 4 hour time period following oral administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate ketoprofen oral gelatin formulation; (b) a 20% nanoparticulate ketoprofen oral gelatin formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle Laboratories (a Division, of American CyanamidGo., Pearl River, NY)).
  • the surface stabilizers in formulations (a)-(c) are polyvinylpyrrolidone (PVP) k29/32 and sodium lauryl sulfate (SLS).
  • PVP polyvinylpyrrolidone
  • SLS sodium lauryl sulfate
  • Figure 2 Shows the blood levels of ketoprofen at 10 min., 15 min., 20 min., and 30 min. following oral administration of four different 50 mg ketoprofen dosage formulations: (a) a 20% nanoparticulate gelatin ketoprofen formulation; (b) a 5% nanoparticulate gelatin ketoprofen formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle).
  • PVP polyvinylpyrrolidone
  • SLS sodium lauryl sulfate
  • the surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS.
  • Figure 3 Shows the blood levels of ketoprofen over a 4 hour time period following buccal administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate gelatin ketoprofen formulation; (b) a 20% nanoparticulate gelatin ketoprofen formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle).
  • the surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS.
  • Figure 4 Shows the blood levels of ketoprofen at 10 min., 15 min., 20 min., and 30 min. following buccal administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate ketoprofen gelatin formulation; (b) a 20% nanoparticulate ketoprofen gelatin formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle).
  • the surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS.
  • the solid or semi-solid gelatin nanoparticulate active agent formulations of the invention comprise at least one nanoparticulate active agent to be administered having an effective average particle size prior to inclusion in the dosage form of less than about 2000 nm, at least one surface stabilizer adsorbed on or associated with the surface of the active agent, and at least one gel forming substance which exhibits gelation sufficient to retain excess water in a solid or semi-solid form, thereby achieving redisperability of the active agent. Such redispersibility can result in improved bioavailability of the active agent.
  • gelatin dosage forms Prior to the present invention, while gelatin dosage forms were desirable, there was an inherent conflict in desiring more water in the dosage form to increase redispersion of the active agent, and knowing that the presence of a significant percentage of water . can result in degradation of the active agent to be delivered. It was unexpectedly discovered that the presence of water does not destabilize or degrade the nanoparticulate active agent in the dosage forms of the invention.
  • the gelatin dosage forms of the present invention which retain excess water, disperse and essentially melt upon administration. The amount of water retained by the gel formulation of the invention is at least the amount required to provide for redispersabihty of the nanoparticulate active agent particles upon administration.
  • Benefits of the gelatin dosage form of the invention can include, but are not limited to: (1) rapid delivery of the active agent, which can correlate with rapid active agent absorption; (2) stability of the active agent, which can include particle size and chemical stability of the active agent; (3) excellent redispersabihty of the active agent upon administration or in a biorelevant media; (4) improved bioavailability of the active agent as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (5) a more consistent bioavailability profile for the active agent, aiding in dosage determination, due to the more consistent active agent particle sizes present in the gelatin dosage form, as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (6) the gelatin dosage form is easily administered, requires minimal chewing, rapidly dissolves, and essentially melts at body temperature; (7) the gelatin dosage form can be formulated to mask the unpleasant taste of an active agent; (8) the gelatin dosage form is particularly useful for infant
  • Porous active agents as used herein means those having a solubility in at least one liquid media of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, or preferably less than about 1 mg/ml, under ambient temperature. Poorly water soluble active agents tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation.
  • stable includes, but is not limited to, one or more of the following parameters: (1) the active agent particles are substantially chemically, stable, as measured by degradent concentrations; (2) the active agent particles do not appreciably flocculate or agglomerate due to interparticle attractive forces or otherwise increase in particle size over time; (3) the physical structure of the active agent particles is not altered over time, such as by conversion from an amorphous phase to crystalline phase; (4) where the active agent has not been subjected to a heating step at or above the melting point of the active agent in the preparation of the nanoparticles of the invention.
  • “TherapeuticaUy effective amount” as used herein with respect to an active agent dosage shall mean the dosage that provides the specific pharmacological response for which the active agent is administered in a significant number of subjects in need of such treatment. It is emphasized that 'therapeuticaUy effective amount,' administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a “therapeuticaUy effective amount” by those skilled in the art. It is to be further understood that active agent dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
  • the solid or semi-solid nanoparticulate active agent gelatin dosage forms of the invention exhibit gelation sufficient to retain excess water in the solid or semi-solid active agent dosage form, which provides for rapid redispersion of the active agent. Such rapid redispersion can preferably correlate with increased bioavailability of the active agent. This is significant because previous gelatin formulations failed to contain water, or sufficient amounts of water, because of stability considerations. When insufficient water is present in a gelatin dosage form, the active agent is not sufficiently dissolved and absorbed into the blood stream following administration because there is little or no redispersabihty of the active agent in vivo.
  • the solid or semi-solid nanoparticulate active agent gelatin dosage forms of the invention preferably redisperse such that the effective average particle size of the redispersed active agent particles is less than about 2 microns. This is significant, as if upon administration the nanoparticulate active agent compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the gelatin dosage form may lose the benefits afforded by formulating the active agent into a nanoparticulate particle size.
  • nanoparticulate active agent compositions benefit from the small particle size of the active agent; if the active agent does not redisperse into the small particle sizes upon administration, then "clumps" or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate active agent system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with a form of the nanoparticulate active agent that does not form such agglomerated particles.
  • the gelatin dosage forms of the invention preferably exhibit dramatic redispersion of the component nanoparticulate active agent particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed active agent particles is less than about 2 microns.
  • a biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media.
  • the desired pH and ionic strength are those that are representative of physiological conditions found in the human body.
  • Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength.
  • Biorelevant pH is well known in the art. For example, in the stomach, the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5. In the small intestine the pH can range from 4 to 6, and in the colon it can range from 6 to 8.
  • Biorelevant ionic strength is also well known, in the art. Fasted state gastric fluid has an ionic strength of about 0J M while fasted state intestinal fluid has an ionic strength of about 0J4.
  • pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc.
  • Representative electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof.
  • electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
  • Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0J M HCl correspond to pH 3, pH 2, and pH 1, respectively.
  • a 0.01 M HCl solution simulates typical acidic conditions found in the stomach.
  • a solution of 0J M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0J M may be employed to simulate fed conditions within the human GI tract.
  • Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride.
  • the redispersed active agent particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, micros
  • Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate.”
  • Exemplary redispersion media includes, but is not limited to, sterile water for injection, saline, dextrose, Lactated Ringer's solution, and Ringers solution.
  • An advantage typically associated with the solid or semi-solid gelatin dosage forms of the invention is a reduction of the time lag between administration of a dose and the physical presentation of the active agent. This lag time is usually associated with the break up of the dosage form and the distribution of the active agent thereafter.
  • a second advantage of the solid or semi-solid gelatin dosage forms is that the gelatin melts at body temperature. Thus, upon administration, the active agent may be absorbed buccally directly into the blood stream, thus reducing the first pass effect of the liver on the overall bioavailability of active agent from a unit dose.
  • This second advantage is enhanced because the incorporation of the nanoparticulate size of the active agent into the solid or semi-solid gelatin formulations of the invention enables rapid dissolution in the oral cavity.
  • This combination of rapid delivery, stability, and improved redispersabihty preferably can achieve increased bioavailability of the active agent as compared to prior known gelatin-containing active agent delivery systems.
  • the gelatin dosage forms of the invention are also superior to nanoparticulate active agent dispersions of the same active agent. This is particularly unexpected as generally liquid dosage forms have greater bioavailability and faster onset of action as compared to sohd or semi-solid dosage forms.
  • the gelatin dosage forms of the invention may provide a more consistent bioavailability profile, which aids in dosage determination, as the gelatin dosage forms of the invention preferably have a narrow active agent particle size range.
  • Gelatin dosage forms having highly variable active agent particle sizes, including large crystals, can result in a variable bioavailability profile from dose to dose because smaller particles dissolve faster than the larger aggregates or larger crystal particles.
  • active agents having a dissolution-rate limited bioavailability such as poorly water soluble active agents, a faster rate of dissolution is associated with greater bioavailability and a slower rate of dissolution is associated with a lower bioavailability.
  • bioavailability is related to the surface area of an administered active agent and, therefore, bioavailability increases with a reduction in the particle size of the dispersed agent.
  • bioavailability With a composition having widely varying particle sizes, bioavailability becomes highly variable and inconsistent and dosage determinations become difficult. This can be particularly problematic for active agents having a narrow preferred dosage range, such as immunosuppressants, chemotherapy agents, etc.
  • the gelatin dosage forms of nanoparticulate active agents of the invention preferably exhibit increased bioavailability, at the same dose of the same active agent, require smaller doses, and show longer plasma half-life as compared to prior conventional active agent formulations.
  • the gelatin dosage forms of nanoparticulate active agents of the invention may have enhanced bioavailability such that the active agent dosage can be reduced as compared to a conventional nbn-nanoparticulate dosage form of the same active agent, which can result in a decrease in toxicity associated with the active agent.
  • greater bioavailability of the gelatin dosage forms of nanoparticulate active agents of the invention can enable a smaller active agent dosage volume. This is particularly significant for patient populations such as the elderly, juvenile, and infant.
  • the gelatin dosage forms of the invention can be formulated for dosages in any volume, but are preferably formulated into equivalent or smaller volumes than existing conventional dosage forms of the same active agent (i.e., non-nanoparticulate or solubihzed active agent formulations).
  • the invention encompasses gelatin dosage forms formulated into a volume which is at least half that of a conventional non-nanoparticulate dosage form of the same active agent. Even smaller dosage volumes are also possible.
  • the maximal dose loading of the gelatin dosage forms of the invention is significantly higher than the maximal dose loading provided by conventional formulations of the same active agents. A dose loading which is double or more than that utilized in conventional, non-nanoparticulate dosage forms of the same active agent is expected to be useful.
  • Preparation of the solid or semi-solid oral gelatin dosage form does not require solubilizing the active agent. This is significant, as prior art gelatin dosage forms required solubilization of the active agent. Such solubilization of an active agent is undesirable, as it can change the pharmacokinetic and pharmacologic characteristics of the active agent. For example, solubilization followed by precipitation of an active agent can result in a modification of the solidification state of the active agent (i.e., whether the active agent is in an amorphous or crystalline form), it can affect the stability of the active agent in the aqueous state, and it can affect how much of the active agent has returned to the solid state.
  • compositions according to the present invention are particularly useful for the specific needs of pediatrics, geriatrics, and patients with dysphagia as well as patients with chronic dosing needs.
  • Solid or semi-solid gelatin active agent delivery formulations are beneficial because of their ease of administration, convenience, and patient-friendly nature. It is estimated that 35% to 50% of the population finds it difficult to swallow tablets and hard gelatin capsules, particularly pediatric and geriatric patients.
  • Solid or semi-solid gelatin active agent delivery formulations of the invention eliminate the need to swallow a tablet or capsule whole, as the dosage form "melts" upon administration.
  • One of the contemplated uses of the solid or semi-solid gelatin nanoparticulate active agent formulations is for pediatric patients.
  • the ability to mold the gelatin into shapes such as those that are pleasing and/or entertaining, including but not limited to, animals, letters, numbers, geometric shapes, characters, etc., is particularly useful for administration to young patients.
  • F. Improved Pharmacokinetic Profiles [0069]
  • the invention also preferably provides gelatin dosage forms of nanoparticulate active agents having a desirable pharmacokinetic profile when administered to mammalian subjects.
  • the desirable pharmacokinetic profile of the gelatin dosage forms preferably includes, but is not limited to: (1) that the T max of an active agent when assayed in the plasma of a mammalian subject following administration is preferably less than the T raax for a conventional, non-nanoparticulate form of the same active agent, administered at the same dosage; (2) that the C max of an active agent when assayed in the plasma of a mammalian subject following administration is preferably greater than the C raax for a conventional, non- nanoparticulate form of the same active agent, administered at the same dosage; and/or (3) that the AUC of an active agent when assayed in the plasma of a mammalian subject following administration, is preferably greater than the AUC for a conventional, non- nanoparticulate form of the same active agent, administered at the same dosage.
  • the desirable pharmacokinetic profile is the pharmacokinetic profile measured after the initial dose of an active agent.
  • the compositions can be formulated in any way as described herein and as known to those of skill in the art.
  • a preferred gelatin dosage form of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, a T max not greater than about 90%>, not greater than about
  • a preferred gelatin dosage form of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, a C max which is at least about 10%, at least about 20%), at least about 30%>, at least about 40%, at least about 50%, at least about 60%o, at least about 70%), at least about 80%, at least about 90%, or at least about 100% greater than the C max exhibited by the non-nanoparticulate formulation of the same active agent.
  • a preferred gelatin dosage composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, an AUC which is at least about 10%, at least about 20%), at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%), at least about 80%, at least about 90%, or at least about 100% greater than the AUC exhibited by the non-nanoparticulate formulation of the same active agent.
  • the gelatin dosage forms of the invention can comprise multiple nanoparticulate active agent compositions of either the same or different active agents. Where the active agent is the same, the compositions can differ in, for example, the active agent particle size or the active agent dosage.
  • the gelatin dosage form can comprise one or more solubihzed or conventional microparticulate particle size active agents.
  • the gelatin dosage form can comprise a first nanoparticulate active agent composition having a nanoparticulate particle size, conferring a short T m and typically a higher C max .
  • This first nanoparticulate active agent composition can be combined with a second composition comprising: (1) the same active agent having a larger (but still nanoparticulate as defined herein) particle size, and therefore exhibiting slower absorption, a longer T max , and typically a lower C max ; (2) the same active agent having a microparticulate particle size or which is solubihzed, exhibiting a longer T- ⁇ , and typically a lower C ⁇ and/or (3) a different active agent having nanoparticulate particle size, microparticulate particle size, or which is solubihzed.
  • the second, third, fourth, etc., active agent compositions can differ from the first, and from each other, for example: (1) in the effective average particle sizes of the active agent; (2) the dosage of the active agent; or (3) in the identity of the active agent. Such a combination composition can reduce the dose frequency required.
  • the second active agent composition has a nanoparticulate particle size, then preferably the active agent particles of the second composition have at least one surface stabilizer associated with the surface of the active agent particles.
  • the one or more surface stabilizers can be the same as or different from the surface stabilizer(s) present in the first active agent composition.
  • nanoparticulate active agent particles can be combined with the microparticulate particles of the same active agent to provide for a gelatin dosage form exhibiting sustained or controlled release.
  • the combination of very small active agent particles, i.e., nanoparticulate active agent particles, in combination with larger active agent particles, i.e., micronized active agent particles, can enable obtaining the simultaneous presentation of immediate-release (IR) and controlled-release (CR) active agent components.
  • IR immediate-release
  • CR controlled-release
  • “nanoparticulate” active agents have an effective average particle size of less than about 2 microns and micronized active agents have an effective average particle size of greater than about 2 microns.
  • nanoparticulate active agent particles representing the IR component
  • micronized active agent particles representing the CR component
  • afford slower in vivo dissolution owing to a comparatively large particle size and small attendant specific surface.
  • IR and CR components representing a wide range of in vivo dissolution rates (and hence, in vivo input rates for absorption) can be engineered through precise control of active agent particle size.
  • compositions can comprise a mixture of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate
  • compositions can comprise a mixture of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate
  • the Pharmacokinetic Profiles of the Active Agent Compositions of the Invention are not Affected by the Fed or Fasted State of the Subject Ingesting the Compositions
  • the invention encompasses a gelatin dosage form of a nanoparticulate active agent wherein the pharmacokinetic profile of the active agent is preferably not substantially affected by the fed or fasted state of a subject ingesting the composition, when administered to a human. This means that there is no substantial difference in the quantity of active agent absorbed or the rate of active agent absorption when the gelatin dosage forms are administered in the fed versus the fasted state.
  • the invention also encompasses a gelatin dosage form of a nanoparticulate active agent in which administration of the gelatm dosage form to a subject in a fasted state is bioequivalent to administration of the gelatin dosage form to a subject in a fed state.
  • "Bioequivalency” is preferably established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both C max and AUC under U.S. Food and Drug Administration regulatory guidelines, or a 90% CI for AUC of between 0.80 to 1.25 and a 90% CI for C max of between 0.70 to 1.43 under the European EMEA regulatory guidelines (T ⁇ is not relevant for bioequivalency determinations under USFDA and EMEA regulatory guidelines).
  • Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant, as with poor subject compliance an increase in the medical condition for which the active agent is being prescribed may be observed.
  • the difference in absorption of the gelatin dosage forms of the invention, when administered in the fed versus the fasted state preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%>, less than about 40%, less than about 30%, less than about 25%o, less than about 20%), less than about 15%, less than about 10%, less than about 5%, or less than about 3%.
  • Bioadhesive gelatin dosage forms of nanoparticulate active agents according to the present invention comprise at least one cationic surface stabilizer, which are described in more detail below.
  • Active Agents [0091] The invention can be practiced with a wide variety of active agents.
  • the active agent is preferably poorly soluble and dispersible in at least one liquid media.
  • Useful liquid dispersion medias include, but are not limited to, water, aqueous salt solutions, safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol.
  • the active agent has a solubility in the liquid dispersion media of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, and more preferably less than about 1 mg/ml.
  • Two or more active agents can be used in combination.
  • an active agent If an active agent is not poorly soluble, it can be conjugated to a salt or other substance to render the active agent poorly soluble. Thus, active agents having, for example, therapeutic, cosmetic, diagnostic, or bioengineering uses are presumed suitable for the invention.
  • the active agent may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers.
  • the active agent may be in a crystalline form, semi-crystalline form, amorphous form, semi- amorphous form, or a combination thereof.
  • the active agent can be selected from a variety of known classes of drugs, including, for example, COX-2 inhibitors, retinoids, anticancer agents, NSATDS, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, dietary supplements, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antiMstamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, anti
  • bioadhesion refers to any attractive interaction between two biological surfaces or between a biological and a synthetic surface.
  • bioadhesive nanoparticulate active agents the term bioadhesion is used to describe the adhesion between the nanoparticulate active agents and a biological substrate (i.e. gastrointestinal mucin, lung tissue, nasal mucosa, etc.). See e.g., U.S. Patent No. 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers," which is specifically incorporated by reference.
  • the bioadhesive gelatin dosage forms of nanoparticulate active agents of the invention are useful in any situation in which it is desirable to apply the compositions to a biological surface.
  • the bioadhesive gelatin dosage forms coat the targeted surface in a continuous and uniform film which is invisible to the naked human eye.
  • a bioadhesive gelatin dosage form of a nanoparticulate active agent slows the transit of the dosage form, and some active agent particles would also most likely adhere to tissue other than the mucous cells and therefore give a prolonged exposure to the active agent, thereby increasing absorption and the bioavailability of the administered dosage.
  • the starting nanoparticulate active agent composition prior to formulation into a solid or semi-solid gelatin dosage form, comprises at least one active agent having an effective average particle size of less than about 2 microns and at least one surface stabilizer adsorbed on or associated with the surface of the active agent.
  • Surface stabilizers useful herein physically adhere on, or associate with, the surface of the nanoparticulate active agent but do not chemically react with the active agent particles or itself. Individual molecules of the surface stabilizer are preferably essentially free of intermolecular cross-linkages.
  • the present invention also includes gel-stabilized nanoparticulate active agent compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
  • compositions can be formulated for administration in solid or semi-solid form.
  • anoretics sympathomimetics, thyroid agents, vasodilators, xanthines, alpha-hydroxy formulations, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, and respiratory illness therapies associated with acquired immune deficiency syndrome.
  • Examples of representative active agents useful in this invention include, but are not limited to, acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin, cisapride, clarithromycin, clonidine, clopidogrel, cyclobenzaprine, cyproheptadine, delavirdine, desmopressin, diltiazem, dipyridamole, dolasetron, enalapril maleate, enalaprilat, famotidine, felodipine, furazolidone, glipizide, irbesartan, ketoconazole, lansoprazole, loratadine, loxapine, mebendazole, mercaptopurine, mihinone lactate,
  • nutraceuticals and dietary supplements are disclosed, for example, in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001), which is specifically incorporated by reference.
  • a nutraceutical or dietary supplement also known [0097] as phytochemicals or functional foods, is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or pharmaceutical effects on the body.
  • nutraceuticals or dietary supplements include, but are not limited to, lutein, folic acid, fatty acids (e.g., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids (e.g., iso- leucine, leucine, lysine, methionine, phenylanine, threonine, tryptophan, and valine), green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics.
  • lutein folic acid
  • fatty acids e.g., DHA and ARA
  • fruit and vegetable extracts e.g., fatty acids (e.g., DHA and ARA), fruit
  • Nutraceuticals and dietary supplements also include bio-engineered foods genetically engineered to have a desired property, also known as "pharmafoods.”
  • pharmafoods bio-engineered foods genetically engineered to have a desired property
  • a description of these classes of active agents and a listing of species within each class can be found in Martindale, The Extra Pharmacopoeia, Twenty-ninth Edition (The Pharmaceutical Press, London, 1989), specifically incorporated by reference.
  • the active agents are commercially available and/or can be prepared by techniques known in the art.
  • Exemplary useful surface stabilizers include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Exemplary surface stabilizers include nonionic, anionic, cationic, ionic, and zwitterionic surfactants. Combinations of more than one surface stabilizer can be used in the invention.
  • surface stabilizers include hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, random copolymers of vinyl pyrrolidone and vinyl acetate, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween
  • Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, poly lysine, polyvinylimidazole, polybrene, polymethylmethacrylate Iximethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrohdone-2-dimethylaminoethyl methacrylate dimethyl sulfate.
  • cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammomum chloride, benzyl-di(2-chloroethyl)ethylammomum bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammomum chloride or bromide, decyl triefhyl ammonium chloride, decyl dimethyl hydroxyethyl ammomum chloride or bromide, C 12 .
  • cationic lipids such as stearyltrimethylammomum chloride, benzyl-di(2-chloroethyl)ethylammomum bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammomum chloride or bromide, dec
  • nonpolymeric primary stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammomum compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NR ⁇ R 2 R 3 R 4 (+) .
  • R r R 4 For compounds of the formula NR I R 2 R 3 R 4 (+) : (i) none of R r R 4 are CH 3 ; (ii) one of R r R 4 is CH 3 ; > (iii) three of R R 4 are CH 3 ; (iv) all of R r R 4 are CH 3 ; (v) two of R r R 4 are CH 3 , one of R r R 4 is C 6 H 5 CH 2 , and one of R r R 4 is an alkyl chain of seven carbon atoms or less; (vi) two of R ⁇ R 4 are CH 3 , one of R R 4 is C 6 H 5 CH 2 , and one of Ri-R 4 is an alkyl chain of nineteen carbon atoms or more; (vii) two of R : -R 4 are CH 3 and one of R r R 4 is the group C 6 H 5 (CH 2 ) n , where n>l; (viii) two of R R 4 are CH 3 , one of R
  • Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydro fluoride, chlorallyhnethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammomum chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylammoethylchloride hydrochloride, cysteine hydrochloride, diethanolammomum POE (10) oletyl ether phosphate, diethanolammomum POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl diocta
  • particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation. [0109] By "an effective average particle size of less than about 2000 nm” it is meant that at least about 50%> of the active agent particles have a particle size less than about 2000 nm when measured by the above techniques.
  • At least about 70%), at least about 90%>, ' at least about 95%>, or at least about 99%> of the active agent particles have a particle size less than the effective average, i.e., less than about 2000 nm.
  • the effective average particle size of the active agent particles is less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm.
  • the value for D50 of a nanoparticulate active agent composition is the particle size below which 50% of the active agent particles fall, by weight.
  • D90 is the particle size below which 90% of the active agent particles fall, by weight.
  • an effective average particle size of greater than about 2 microns it is meant that at least 50%> of the active agent particles have a particle size greater than about 2 microns, when measured by the above techniques.
  • the gel forming substance can be a natural, semi-synthetic, or synthetic gelatin, or a chemical or physical gel. At least one natural or synthetic gel forming substance is used in the inventive formulations.
  • Natural gel forming substances include but are not hmited to algal (e.g., agar, furcelleran, alginate, and carrageenan), botanical (e.g., plant extracts, gum arabic, tragacanth, karaya, ghatti seed gums, guar gum, and locust bean gum), microbial (e.g., xanthan, puUulan, scleroglucan, curdlan, dextran, and gellan), animal (e.g., chitin and chitosan, chrondroitin sulfate, dermatan sulfate, heparain, keratan sulfate, and hyaluro ⁇ ic acid
  • algal e.g., agar
  • Synthetic gel forming substances include but are not limited to water-soluble polymers containing complexing groups, which can be crosslmked to form gels.
  • water-soluble monomers include but are not limited to acrylic acid, methacrylic acid, acrylamide, N-alkylacrylamide, methacrylamide, vinylpyrrolidone, methyl methacrylate, hydroxyethyl methacrylate, and vinyl pyridine which can be crosslinked with, e.g., low molecular weight crosslinking agents, such as N,N'-methylenebisacrylamide and macromolecules, such as proteins.
  • compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients. Such excipients are known in the art. [0117] Because many drugs have an unpleasant taste, the use of taste masking excipients may be added to the gelatin composition to achieve a composition which is pleasant tasting and easily administered. In addition to pleasant tasting flavors, interesting • coloring agents can be added to the formulation.
  • Such taste masking can be accomplished, for example, by the addition of one or more sweet tasting excipients, by coating the nanoparticulate active agent and one or more surface stabilizers with a sweet tasting excipient, and/or by coating a dosage form of the nanoparticulate active agent, one or more surface stabilizers, and excipients with a sweet tasting excipient.
  • filling agents are lactose monohydrate, lactose anhydrous, and various starches
  • binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystaUine cellulose, such as Avicel ® PHI 01 and Avicel ® PHI 02, microcrystaUine cellulose, and silicifized microcrystaUine cellulose (SMCC).
  • Suitable lubricants including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil ® 200; talc, stearic acid, magnesium stearate, calcium stearate, and silica gel.
  • sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame.
  • flavoring agents are Magnasweet ® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like.
  • preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other .esters of parahydroxybenzbic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride.
  • Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystaUine cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing.
  • examples of diluents include microcrystaUine cellulose, such as Avicel ® PH101 and Avicel ® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose ® DCL21; dibasic calcium phosphate such as Emcompress ® ; mannitol; starch; sorbitol; sucrose; and glucose.
  • Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof.
  • effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate.
  • Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts.
  • Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate.
  • acid component of the effervescent couple may be present.
  • nanoparticulate Active Agent Composition and Gel forming Substance
  • the relative amount of nanoparticulate active agent composition in the gelatin dosage forms of the invention can vary widely and can depend upon, for example, the active agent and surface stabilizer(s) selected for delivery, the melting point of the active agent and surface stabilizer, the water solubility of the active agent and surface stabilizer, the surface tension of water solutions of the active agent and surface stabilizer, etc.
  • the active agent may be present in any amount which is sufficient to elicit a therapeutic effect.
  • the concentration of the at least one active agent can vary from about 99.5%> to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the active agent and surface stabilizer, not including other excipients.
  • the concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%), from about 5.0% to about 99.9%, and from about 10.0% to about 99.5%o, by weight, based on the total combined dry weight of the active agent and surface stabilizer, not including other excipients.
  • the at least one gel forming substance can be present in an amount of about 0.5%) to about 60%, about 3% to about 40%>, or about 5%o to about 20%, by weight, based on the total weight of the active agent, surface stabilizer, and gel forming substance.
  • a method of preparing solid or semi-solid gelatin dosage forms of nanoparticulate active agents comprises combining: (1) a nanoparticulate active agent composition of at least one active agent and at least one surface stabilizer, wherein the active agent has an effective average particle size of less than about 2000 nm, and (2) at least one gel forming substance, which exhibits gelation sufficient to retain excess water in a solid or semi-solid form, to form a solid dose matrix surrounding the nanoparticulate active agent composition.
  • the method does not comprise solubilizing the active agent.
  • Nanoparticulate active agent compositions can be made using, for example, milling, precipitation, or homogenization techniques. Exemplary methods of making nanoparticulate active agent compositions are described in U.S. Patent No. 5,145,684. Methods of making nanoparticulate active agent compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,862,999 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No.
  • the solid or semi-solid gelatin nanoparticulate matrix composition is prepared by mixing gelatin at an appropriate concentration and warming the mixture in a water bath, such as at about 50°C.
  • a warmed amount of a nanoparticulate active agent dispersion (comprising at least one active agent and at least one surface stabilizer) is slowly added to the molten gelatin with an overhead mixer and mixed, such as for about 10 minutes.
  • the nanoparticulate active agent dispersion can also be heated in a water bath of about 50°C.
  • the molten mixture is homogenized. When the homogenization is completed, the formulation is dispensed into a mold and refrigerated until formed.
  • the gelatin formulations of the invention can be formulated into solid or semi- liquid dosage formulations, such as controlled release formulations, solid dose fast melt formulations, lyophilized formulations, aerosol formulations, tablets, capsules, lozenges, etc.
  • Milling an active agent to obtain a nanoparticulate dispersion for subsequent formulation into a solid or semi-solid gel dosage form comprises dispersing particles of at least one active agent in a liquid dispersion media in which the active agent is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the active agent to the desired effective average particle size.
  • the active agent particles can be reduced in size in the presence of at least one surface stabilizer.
  • the active agent particles can be contacted with one or more surface stabilizers after attrition.
  • Other compounds, such as a diluent, can be added to the
  • Dispersions can be manufactured continuously or in a batch mode.
  • Such a method comprises dispersing active agent particles in a liquid dispersion media, followed by subjecting the dispersion to homogenization to reduce the particle size of the active agent to the desired effective average particle size.
  • the active agent 25 particles can be reduced in size in the presence of at least one surface stabilizer.
  • the active agent particles can be contacted with one or more surface stabilizers either before or after particle size reduction.
  • Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition either before, during, or after the size reduction process.
  • Dispersions can be manufactured continuously or in a batch mode.
  • the present invention provides a method of treating a subject, including humans and animals, requiring the rapid availability and ease of administration of an active agent, and in particular a poorly water soluble active agent.
  • the method comprises administering to the subject an effective amount of a solid or semi-solid gelatin dosage form of a nanoparticulate active agent.
  • the gelatin dosage form melts, and the component nanoparticulate active agent particles redisperse, upon administration.
  • the composition can be formulated into any suitable dosage form, such as a immediate release formulation, controlled release formulation, fast melt formulation, delayed release formulation, extended release formulation, pulsatile release formulation, and mixed immediate release and controlled release formulation.
  • An alternative method of administration involves administering an effective amount of a solid or semi-solid gelatin dosage form of a nanoparticulate active agent which redisperses upon administration to a fasted patient.
  • a fasted patient is defined as a patient that has not ingested food for a period of time prior to administration of the gelatin dosage form.
  • the gelatin dosage forms of the invention have an enhanced efficacy in a fasted patient in comparison to administration of a nanoparticulate active agent dispersion.
  • compositions of the invention are administered via any pharmaceutically acceptable method to a subject in need thereof using a level of active agent that is sufficient to provide the desired physiological effect, such as oral, rectal, vaginal, local, buccal, and topical administration.
  • a level of active agent that is sufficient to provide the desired physiological effect
  • the subject may be a domestic animal or pet but preferably is a human subject.
  • the level of active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts, such as Goodman and Gillman and the Physician's Desk Reference.
  • Example 1 The purpose of this example was to prepare a nanoparticulate gelatin formulation of Compound A, having analgesic properties.
  • a nanoparticulate dispersion of Compound A was prepared, comprising 20%> Compound A, 4%> Plasdone® S630 (a copolymer of vinyl pyrrolidone and vinyl acetate from ISP), and 0.8% dioctylsulfosuccinate (DOSS).
  • the dispersion was prepared by milling Compound A, Plasdone ® S630, and DOSS with a Dyno ® -Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 300 cc recirculation chamber using a 500 ⁇ m milling media of type Polymill 500 ® for 6 hrs at 10°C. [0145]
  • the initial particle size was measured using a Horiba LA-910 Static Light
  • the mean particle size of Compound A dispersion was 138 nm with a D90 of 202 nm.
  • the solid gelatin matrix of nanoparticulate Compound A was prepared by warming a 20% gelatin: 80% water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath.
  • the nanoparticulate dispersion of 20% Compound A, 4%> Plasdone® S630, and 0.8% dioctylsulfosuccinate (DOSS) was heated in a 50°C water bath until the dispersion reached 50°C.
  • the dispersion was slowly added to the molten gelatin in a 1 : 1 ratio (nanoparticulate Compound A dispersion: gelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate Compound A dispersion had the following composition: 10%> Compound A, 2% Plasdone® S630, 0.4% ⁇ dioctylsulfosuccinate (DOSS), and 10%> gelatin with the remaining 77.6%o of the composition being water.
  • a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, the formulation was dispensed into a mold and refrigerated until formed.
  • Example 2 The purpose of this example was to prepare a nanoparticulate Ketoprofen gelatin formulation.
  • Ketoprofen is a well-known nonsteroidal anti-inflammatory agent (NSATD).
  • a nanoparticulate Ketoprofen dispersion was prepared, comprising 30% > ketoprofen and 3%o polyvinylpyrrolidone (PVP k90).
  • the dispersion was prepared by milling ketoprofen and PVP with a Dyno ® -Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 150 cc batch chamber using a 500 ⁇ m milling media of type Polymill 500 ® for 2 hrs at 10°C.
  • the initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA).
  • the mean particle size of the ketoprofen dispersion was 183 nm, with a D50 and D90 of 178 nm and 249 nm, respectively.
  • the solid gelatin matrix of nanoparticulate ketoprofen was prepared by warmthing a 20%> gelatin: 80%> water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath.
  • the dispersion was slowly added to the molten gelatin in a 1 J ratio (nanoparticulate ketoprofen dispersion: gelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition; 15% ketoprofen, 1.5%o PVP, and 10% gelatin with the remaining 73.5% of the composition being water.
  • a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, the formulation was dispensed into a mold and refrigerated until formed.
  • Example 3 The purpose of this example was to compare the redispersion properties of various solid or semi-solid nanoparticulate naproxen gelatin dosage formulations.
  • Naproxen is a well-known anti-inflammatory, analgesic, and antipyretic agent.
  • a first nanoparticulate dispersion of naproxen was prepared, comprising 20% naproxen and 2% PVP k90.
  • the dispersion was prepared by milling naproxen and PVP with a Dyno ® -Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 300 cc batch chamber using a 500 ⁇ m milling media of type Polymill 500 ® for 5 hrs at 10°C.
  • the initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA).
  • the mean particle size of the first naproxen dispersion was 154 nm, with a D50%> and a D90%> of 145 and 222 nm, respectively.
  • a second nanoparticulate naproxen dispersion was prepared, comprising 40% naproxen and 4%> PVP k90.
  • the dispersion was prepared by milling naproxen and PVP in a similar manner to the first dispersion.
  • the initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA).
  • the mean particle size of the second naproxen dispersion was 158 nm, with a D50%> and a D90% of 152 and 216 nm, respectively.
  • Two gelatin formulations of nanoparticulate naproxen were prepared utilizing the two nanoparticulate naproxen compositions.
  • the first solid gelatin matrix of nanoparticulate naproxen was prepared by warming a 10% gelatin: 90%o water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath.
  • the nanoparticulate dispersion of 20%> naproxen and 2%> PVP was heated in a 50°C water bath until the dispersion reached 50°C.
  • the dispersion was slowly added to the molten gelatin in a 0.25:1 ratio (nanoparticulate naproxen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate naproxen dispersion had the following composition: 4% naproxen, 0.4%> PVP, and 8% gelatin with the remaining 87.6% of the composition being water.
  • the second solid gelatin matrix of nanoparticulate naproxen was prepared by warming a 30% gelatin: 70% water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath.
  • the nanoparticulate naproxen dispersion of 40%o naproxen and 4% PVP was heated in a 50° C water bath until the dispersion reached 50°C.
  • the dispersion was slowly added to the molten gelatin in a 1:0.5 ratio (nanoparticulate naproxen dispersio gelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate naproxen dispersion had the following composition; 26.7% naproxen, 2.7% PVP, and 10%) gelatin with the remaining 60.6% of the composition being water.
  • a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes.
  • each formulation was dispensed into a mold and refrigerated until formed.
  • the two gelatin formulations were redispersed in water at 35-40°C. Naproxen particle size following redispersion was measured using a Horiba LA910 particle sizer. The results of the redispersion tests are shown in Table 1, below.
  • Example 4 The purpose of this example was to investigate the redispersibility properties of the semi-solid gelatin nanoparticulate Compound A dosage formulation manufactured according to Example 1.
  • the composition of the dosage form was 10% Compound A, 2%o Plasdone® S630, 0.4% dioctylsulfosuccinate (DOSS), and 10% gelatin with the remaining 77.6% of the composition being water.
  • DOSS dioctylsulfosuccinate
  • the gelatin formulation was redispersed in Simulated Gastric Fluid (SGF) at
  • Compound A particle size was measured using a Horiba LA910 particle sizer. The results of the redispersion tests are shown in Table 2, below.
  • Example 5 The purpose of this example was to investigate the redispersibility properties of the semi-solid gelatin nanoparticulate ketoprofen dosage formulation manufactured according to Example 2.
  • the composition of the dosage form was 15% ketoprofen, 1.5%> PVP, and 10%) gelatin with the remaining 73.5% of the composition being water.
  • the gelatin formulation was redispersed in water at 35-40°C. Ketoprofen particle size was measured using a Horiba LA910 particle sizer. The results of the redispersion tests in water and simulated gastric fluid (SGF), are shown in Table 3, below.
  • Example 6 The purpose of this example was to evaluate the in vivo performance of nanoparticulate ketoprofen gelatin formulations admimstered orally to fasted beagles.
  • ketoprofen formulations were used in the study: (1) commercial ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle), having an approximate particle size of 500 microns; (2) a nanoparticulate ketoprofen dispersion, preparation of which is described below; (3) a 5%> soft oral gelatin formulation, preparation of which is described below; and (4) a 20% hard oral gelatin formulation, preparation of which is described below.
  • a nanoparticulate dispersion of ketoprofen was prepared, comprising 30%o ketoprofen, 3% PVP k29/32, and 0.15% sodium lauryl sulphate (SLS).
  • the dispersion was prepared by milling ketoprofen, PVP and SLS with a NanoMill ® -2 (Mfg.: Netzch, Exton, P.A., U.S.A.) using a 500 ⁇ m milling media of type Polymill 500 ® at 10°C until the desired particle size was achieved.
  • the initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA).
  • the mean particle size of the Ketoprofen dispersion was 153 nm, with a D50%> and a D90%> of 148 and 208 nm, respectively.
  • Two gelatin formulations of nanoparticulate ketoprofen were prepared utilizing the nanoparticulate ketoprofen composition.
  • the nanoparticulate ketoprofen dispersion of comprising 30% ketoprofen, 3% PVP k29/32, and 0.15% SLS was heated in a 50°C water bath until the dispersion reached 50°C.
  • the warmed ketoprofen dispersion was then slowly added to the molten gelatin in a 1 : 1 ratio (nanoparticulate ketoprofen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition: 10%> ketoprofen, 1% PVP, 0.5% SLS and 5%> gelatin with the remaining 83.5% of the composition being water.
  • the nanoparticulate ketoprofen dispersion of comprising 30% ketoprofen, 3% PVP k29/32, and 0.15% SLS was heated in a 50°C water bath until the dispersion reached 50°C.
  • the warmed ketoprofen dispersion was then slowly added to the molten gelatin in a 1:1 ratio (nanoparticulate ketoprofen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes.
  • the resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition: 10% ketoprofen, 1% PVP, 0.5% SLS and 20%) gelatin with the remaining 68.5% of the composition being water.
  • a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, each formulation was dispensed into a mold and refrigerated until formed.
  • Twenty dogs were used in the study.
  • ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle), having an approximate particle size of 500 microns.
  • 4 dogs were administered a 50 mg dose of a nanoparticulate crystalline dispersion of ketoprofen (NCD);
  • CCD nanoparticulate crystalline dispersion of ketoprofen
  • 4 dogs were administered a 50 mg dose of ketoprofen in a 5%> soft oral gelatin formulation; and
  • 4 dogs were administered a 50 mg dose of ketoprofen in a 20%> hard oral gelatin formulation.
  • Administration was by oral gavage to the back of the throat, whereby the dogs swallowed the formulations.
  • the gelatin formulations had a faster onset of action, as the mean peak plasma level concentration (C max ) of the 5%> gelatin formulation was 17.5 ⁇ g/ml at twenty minutes after administration, which corresponds to an onset of action rate as determined from blood plasma levels of 0.85 ⁇ g/min.
  • the hard gelatin (20%) gelatin) also provided rapid onset of action and exhibited a C max of 19.9 ⁇ g/ml, which corresponds to an onset of action rate as determined from blood plasma levels of 1 ⁇ g/min.
  • the commercial dosage exhibited a C max of 10.6 ⁇ g/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.5 ⁇ g/min.
  • Example 7 The purpose of this example was to evaluate the in vivo performance of nanoparticulate ketoprofen gelatin formulations administered bucally to fasted beagles.
  • the ketoprofen formulations used in this study were the same as in example 6.
  • Twenty dogs were used in the study.
  • the gelatin formulations had a faster onset of action, as the mean peak plasma level concentration (C max ) of the soft gelatin dosage form (5% gelatin) was 14.89 ⁇ g/ml at twenty minutes after administration, which corresponds to an onset of action rate as determined from blood plasma levels of 0.75 ⁇ g/min.
  • the hard gelatin dosage form (20% gelatin) also provided rapid onset of action and exhibited a C max of 15.95 ⁇ g/ml, which corresponds to an onset of action rate as determined from blood plasma levels of 0.67 ⁇ g/min.
  • the commercial dosage exhibited a C raax of 10.6 ⁇ g/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.5 ⁇ g/min.
  • the ketoprofen NCD performed similarly, exhibiting a C max of 12.37 ⁇ g/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.56 ⁇ g/min.
  • Figure 4 clearly shows that the soft nanoparticulate gel dosage form (5% gelatin) initially exhibits the highest blood concentration of ketoprofen, whereas the hard nanoparticulate gel dosage form (20% > nanogel), while exhibiting a slower onset that the soft nanogel, ultimately delivers more ketoprofen from the gelatin.

Abstract

Disclosed is a solid or semi-solid gelatin nanoparticulate active agent dosage form comprising at least one nanoparticulate active agent and at least one glel forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gelatin form. The active agent particles have an effective average diameter prior to inclusion in the dosage form of less than about 2000 mn. The dosage form of the invention has the advantages of easy administration combined with rapid dissolution of the active agent following administration.

Description

GEL-STABILIZED NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
FIELD OF THE INVENTION
[0001] The present invention relates to a solid or semi-solid gelatin dosage formulation comprising a nanoparticulate active agent. Prior to incorporation in the dosage form, the nanoparticulate active agent preferably has an effective average particle size of less than about 2 microns.
BACKGROUND OF THE INVENTION
A. Background Related to Nanoparticulate Compositions [0002] Nanoparticulate active agent compositions, first described in U.S. Patent No.
5,145,684 ("the '684 patent"), are particles consisting of a poorly soluble active agent having adsorbed onto or associated with the surface thereof a non-crosslinked surface stabilizer. The '684 patent also describes methods of making such nanoparticulate active agent compositions. Nanoparticulate compositions are desirable because with a decrease in particle size, and a consequent increase in surface area, a composition is rapidly dissolved and absorbed following administration. [0003] Methods of making nanoparticulate active agent' compositions are described, for example, in U.S. Patent Nos. 5,518,187 and 5,862,999, both for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,718,388, for "Continuous Method of Grinding Pharmaceutical Substances;" and U.S. Patent No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles." [0004] Nanoparticulate active agent compositions are also described, for example, in U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for "Method to Reduce Particle Size Growth During Lyophilization;" 5,318,767 for "X-Ray Contrast Compositions Useful in Medical Imaging;" 5,326,552 for "Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" 5,328,404 for "Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;" 5,336,507 for "Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;" 5,340,564 for "Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;1' 5,346,702 for "Use of Non-Ionic Cloud Point Modifiers to Minimize Nanoparticulate Aggregation During Sterilization;" 5,349,957 for "Preparation and Magnetic Properties of Very Small Magnetic-Dextran Particles;" 5,352,459 for "Use of Purified Surface Modifiers to Prevent Particle Aggregation During Sterilization;" 5,399,363 and 5,494,683, both for "Surface Modified Anticancer Nanoparticles;" 5,401,492 for "Water Insoluble Non-Magnetic Manganese Particles as Magnetic Resonance Enhancement Agents;" 5,429,824 for "Use of Tyloxapol as a Nanoparticulate Stabilizer;" 5,447,710 for "Method for Making Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;" 5,451,393 for "X-Ray Contrast Compositions Useful in Medical Imaging;" 5,466,440 for "Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents in Combination with Pharmaceutically Acceptable Clays;" 5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation;" 5,472,683 for "Nanoparticulate Diagnostic Mixed Carbamic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,500,204 for "Nanoparticulate Diagnostic Dimers as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,518,738 for "Nanoparticulate NSATD Formulations;" 5,521,218 for "Nanoparticulate Iododipamide Derivatives for Use as X-Ray Contrast Agents;" 5,525,328 for "Nanoparticulate Diagnostic Diatrizoxy Ester X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,543,133 for "Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;" 5,552,160 for "Surface Modified NSATD Nanoparticles;" 5,560,931 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" 5,565,188 for "Polyalkylene Block Copolymers as Surface Modifiers for Nanoparticles;" 5,569,448 for "Sulfated Non-ionic Block Copolymer Surfactant as Stabilizer Coatings for Nanoparticle Compositions;" 5,571,536 for "Formulations of Compounds as Nanoparticulate Dispersions in Digestible Oils or Fatty Acids;" 5,573,749 for "Nanoparticulate Diagnostic Mixed Carboxylic Anydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,573,750 for "Diagnostic Imaging X-Ray Contrast Agents;" 5,573,783 for "Redispersible Nanoparticulate Film Matrices With
Protective Overcoats;" 5,580,579 for "Site-specific Adhesion Within the GI Tract Using Nanoparticles Stabilized by High Molecular Weight, Linear Poly(ethylene Oxide) Polymers;" 5,585,108 for "Formulations of Oral Gastrointestinal Therapeutic Agents in Combination with Pharmaceutically Acceptable Clays;" 5,587,143 for "Butylene Oxide-Ethylene Oxide Block Copolymers Surfactants as Stabilizer Coatings for Nanoparticulate Compositions;" 5,591,456 for "Milled Naproxen with Hydroxypropyl Cellulose as Dispersion Stabilizer;" 5,593,657 for "Novel Barium Salt Formulations Stabilized by Non-ionic and Anionic Stabilizers;" 5,622,938 for "Sugar Based Surfactant for Nanocrystals;" 5,628,981 for "Improved Formulations of Oral Gastrointestinal Diagnostic X-Ray Contrast Agents and Oral Gastrointestinal Therapeutic Agents;" 5,643,552 for "Nanoparticulate Diagnostic Mixed Carbonic Anhydrides as X-Ray Contrast Agents for Blood Pool and Lymphatic System Imaging;" 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;" 5,718,919 for "Nanoparticles Containing the R(-)Enantiomer of Ibuprofen;" 5,747,001 for "Aerosols Containing Beclomethasone Nanoparticle Dispersions;" 5,834,025 for "Reduction of Intravenously Administered Nanoparticulate Formulation Induced Adverse Physiological Reactions;" 6,045,829 "Nanocrystalline Formulations of Human Immunodeficiency Virus (HTV) Protease mhibitors Using Cellulosic Surface Stabilizers;" 6,068,858 for "Methods of Making Nanocrystalline Formulations of Human Immunodeficiency Virus (HTV) Protease Inhibitors Using Cellulosic Surface Stabilizers;" 6,153,225 for "Injectable Formulations of Nanoparticulate Naproxen;" 6,165,506 for "New Solid Dose Form of Nanoparticulate Naproxen;" 6,221,400 for "Methods of Treating Mammals Using Nanocrystalline Formulations of Human immunodeficiency Virus (HTV) Protease Inhibitors;" 6,264,922 for "Nebulized Aerosols Containing Nanoparticle Dispersions;" 6,267,989 for "Methods for Preventing Crystal Growth and Particle Aggregation in Nanoparticle Compositions;" 6,270,806 for "Use of PEG-Derivatized Lipids as Surface Stabilizers for Nanoparticulate Compositions;" 6,316,029 for "Rapidly Disintegrating Solid Oral Dosage Form," 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate;" 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers;" 6,431,478 for "Small Scale Mill;" 6,432,381 for "Methods for Targeting Drug Delivery to the Upper and/or Lower Gastrointestinal Tract;" 6,582,285 for "Apparatus for Sanitary Wet Milling;" and 6,592,903 for "Nanoparticulate Dispersions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate;" all of which are specifically incorporated by reference. In addition, U.S. Patent Application No. 20020012675 Al, published on January 31, 2002, for "Controlled Release Nanoparticulate Compositions," and International Application No. WO 02/098565, published on December 12, 2002, describe nanoparticulate active agent compositions, and are specifically incorporated by reference. [0005] Amorphous small particle compositions are described, for example, in U.S.
Patent Nos. 4,783,484 for "P articulate Composition and Use Thereof as Antimicrobial Agent;" 4,826,689 for "Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;" 4,997,454 for "Method for Making Uniformly-Sized Particles From Insoluble Compounds;" 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;" and 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter." None of these references, or any other reference that describes nanoparticulate compositions, relates to a rapidly dissolving solid or semi-solid gelatin dosage form comprising a nanoparticulate active agent.
B. Background Related to Dosage Formulations [0006] Drug products are currently designed for three groups of individuals: infants, pediatrics, and adults. The needs of infants are different from those of children 2 to 12 years of age, and the needs of children are different from those of adults. Moreover, the needs of the elderly population are different than those of other adults. Another category of individuals needing an alternative drug delivery form are patients with chronic dosage regimens. Repeated dosing of tablets or pills may become problematic for patients having a need for daily dosage regimens. Thus, an alternative dosage form is needed for a variety of patient populations. [0007] Pediatric patients have difficulty swallowing until they reach the age of about
10-16 years old. Younger pediatric patients generally take either chewable tablets, crush and mix regular tablets with food/juice, or take a liquid dosage form. Chewable tablets, generally a good dosage form, do not always sufficiently mask the taste of the active agent. Crushing and mixing regular tablets with food or juice is time-consuming, messy, and not always practical. The difficulty of liquid dosage forms, e.g., syrups, is that they are bulky, do not always taste good, and can be unstable as compared to a solid dosage form, such as a tablet. A practical and new dosage form would be of value for these patients. [0008] With advancements in medical science and the focus on healthy lifestyles, there is projected growth of the elderly population in the U.S. and abroad. Currently, the U.S. population of persons 65 years of age or older receives nearly 30% of the medications prescribed. Moreover, it is anticipated that there may be a rise in the demand for drugs by the elderly. In spite of the disproportionately large demand for prescription pharmaceuticals among the elderly, relatively little attention has been directed to meeting the unique pharmacotherapeutic needs of this age group. [0009] Many older patients experience difficulty in swallowing tablets or capsules and yet the vast majority of dosage forms administered to the elderly are tablets or capsules. Uncoated tablets are convenient and economical to manufacture but are often difficult to swallow and frequently cause discomfort by "hanging" in the throat. Coated tablets and capsules are somewhat easier to swallow but with increasing age and the large number of drug products that are administered to a single individual, this is a source of apprehension. Liquid dosage forms are relatively easy to administer but are more costly, easily spilled, often do not taste good, occupy large volumes of space per dosage unit, and possess stability problems. [0010] As is evident, the needs of the elderly differ from those of other populations and deserve special attention in new drug development, product formulation, product packaging, product labeling, patient information, and product marketing and sales. A practical and new dosage form would be of value for these patients as well as others.
C. Background Related to Gelatin Dosage Forms [0011] A gelatm drug delivery system would be beneficial in achieving ease of administration in both young, older, and chronic dosage patients. However, such a dosage system must exhibit sufficient stability and bioavailability. Without sufficient bioavailability and active agent stability, ease of administration is just a single step in the process of pharmaceutical therapy. Prior art gelatin dosage forms have been unable to solve this dual necessity of bioavailability in combination with active agent stability. [0012] The most typical gelatin drug delivery formulations comprise gelatin coated tablet formulations and gelatin encapsulated solid cores or liquid cores of pharmaceutical agents. One such example is found in U.S. Patent No. 6,197,787 to Franson et al., which discloses a concentrated drug solution for a soft gelatin capsule filling consisting essentially of: (a) a poorly soluble organic acid drug, such an analgesic, anti-inflammatory agent, anthelmintic, etc.; (b) propylene glycol; (c) sodium hydroxide; and (d) water. However, this dosage formulation is a gelatin capsule and not a solid or semi-solid gelatm formulation. [0013] Another example of a soft gelatin capsule is found in U.S. Patent No. 6,217,902 to Tanner et al. Tanner et al. disclose a soft gelatin capsule comprising a suspension of a solid phase in a liquid phase, with the solid phase consisting of encapsulated beads having a mean diameter of from about 149 μm to 2500 μm. The beads comprise a coating effective to prevent interaction of the active agent with the liquid phase or the soft gelatin capsule. Tanner et al. fail to disclose a solid or semi-solid gelatin formulation. [0014] An example of a gelatin dosage form has been disclosed by Wunderlich in
U.S. Patent No. 5,932,245 ("the '245 patent"). This patent is directed to a dosage formulation that provides: (a) an inner phase comprising at least one nanoparticle compound having an average size ranging from 10 to 800 nanometers; and (b) an outer phase comprising gelatin, collagen hydrolyzates, or mixtures thereof. The inner phase of this composition is negatively charged and the outer phase is positively charged when the dosage formulation is dissolved in an aqueous solution having a pH of less than 9.5, or the inner phase is positively charged and the outer phase is negatively charged when the dosage formulation is dissolved in an aqueous solution having a pH of higher than 3.5. [0015] This reference differs from the present invention in several aspects. First, the '245 patent requires solubilization of the active agent as part of the process of making the described nanosol compositions. The solubilization is achieved either through the use of a solvent (col. 17, lines 30-34), followed by evaporation of the solvent, or through modification of the pH of the gelatin. For example, an active agent is dissolved in ethanol, isopropanol, methanol, or acetone (col. 18, lines 32-36; col. 20, lines 18-20 and 44-48; col. 22, lines 4-5 and 29; col. 23, lines 30-32) or the active agent is dissolved in the gelatin via modifying the pH of the gelatin (col. 18, lines 52-55; col. 21, lines 23-28 and 43-50; col. 22, lines 61-67). Such solubilization of an active agent is undesirable, as solubilization affects the various properties of the active agent, such as the solidification state of the active agent (i.e., whether the active agent is in an amorphous or crystalline form), stability of the active agent in the aqueous state, how much of the active agent has returned to the solid state, etc. Such solubilization is required because in the compositions of the '245 patent, the gelatin functions to stabilize the nanoparticles of the active agent, as pictured below:
Figure imgf000008_0001
[0016] The only way to have the gelatin composition "surround and stabilize" the active agent in the composition of the '245 patent is to first solubilize the active agent in the gelatin, or in a solvent followed by mixing the solvent/active agent solution with the gelatin solution and subsequent evaporation of the solvent. [0017] This is in contrast to traditional nanoparticulate drugs, which do not require solubilization of the active agent. Rather, such compositions utilize a surface stabilizer, such as a surfactant, to stabilize the nanoparticulate size of the active agent following particle size reduction via, for example, milling or homogenization. See e.g., U.S. Patent No. 5,145,684 for "Surface Modified Nanoparticulate Drugs." However, the '245 patent teaches that the use of surfactants is undesirable in the disclosed compositions because such surfactants can have side effects and possible toxicity. See col. 4, lines 12-14. [0018] Finally, another drawback to the formulation of the '245 patent is that it does not retain excess water, which is essential for effective redispersabihty, and hence this dosage form may exhibit poor pharmaceutical bioavailability. This is likely because the gelatin formulation of the '245 patent is not a hydrated gelatin. [0019] Similarly, U.S. Patent No. 6,066,332 ("the '332 patent") to Wunderlich et al. describes a gelatin dosage form containing ibuprofen, having a particle size of from 10 to 800 nanometers, in the form of a nanosol. As with the compositions of the '245 patent, the '332 patent requires solubilization of ibuprofen to make the described gelatin formulations. See e.g., col. 8, line 60, through col. 9, line 5; col. 9, lines 15-16 and 31-34. The ibuprofen is dissolved in a solvent such as ethanol, isopropanol, methanol, or acetone (col. 8, lines 60-62; col. 9, lines 31-34; col. 16, lines 13-15), or the ibuprofen is dissolved in the gelatin via modifying the pH of the gelatin (col. 9, lines 10-16; col. 15, lines 28-35). Such solubilization of an active agent such as ibuprofen is undesirable, as described above. [0020] Moreover, as with the '245 patent, another drawback to the formulation of the '332 patent is that it does not retain excess water, which is essential for effective redispersabihty, and hence this dosage form may exhibit poor pharmaceutical bioavailability. [0021] Another example of a gelatin dosage form is disclosed by Allen et al. in U.S. Patent No. 6,066,337. This patent is directed to a rapidly dissolving pharmaceutical dosage form produced by combining a particulate support matrix with a pharmaceutical ingredient to form a dosage mixture, followed by forming the dosage mixture into a dosage form. When introduced into an aqueous environment, the dosage form is substantially completely disintegrable within less than about 20 seconds. The particulate support matrix is formed by providing an aqueous composition comprising: (a) an aqueous medium, (b) a support agent comprising a non-hydro lyzed gelatin component having a predetermined net charge, (c) a hydrolyzed gelatin component having a predetermined net charge of the same sign as the non- hydrolyzed gelatin component, (d) a bulking agent, and (e) a volatilizing agent. The hydrolyzed gelatin component has a solubility in aqueous solution greater than that of the non-hydrolyzed component. The aqueous composition is introduced as droplets into a drying chamber heated to a temperature sufficient to cause evaporation of substantially all of the aqueous medium and volatilizing agent from the droplets leaving the support agent in a dried particulate form comprising the particulate support matrix. This formulation fails to retain excess water, which is essential for effective redispersabihty, and hence the Allen et al. formulation exhibits poor pharmaceutical bioavailability. [0022] None of the described prior art teaches a rapidly disintegrating gelatin-based solid or semi-solid dosage form in which an active and stable ingredient is in a nanoparticulate form, which does not require solubilization of the active agent as part of the process of making the dosage form, and wherein the gel-forming substance retains excess water, thereby providing sufficient pharmaceutical bioavailability. This is significant because the prior art gelatin drug delivery systems fail to retain water in the gel matrix, which therefore inhibits or prevents redispersabihty, and hence the prior art gelatin formulations exhibit poor pharmaceutical bioavailability. Moreover, prior art gelatin dosage forms required solubilization of component active agents, which is undesirable as solubilization of an active agent can change the active agent's pharmacological and pharmacokinetic characteristics. [0023] There is a need in the art for drug dosage forms having ease of administration, active agent stability, and increased pharmaceutical bioavailability for active agents. The present invention satisfies these needs.
SUMMARY OF THE INVENTION [0024] This invention is directed to the surprising and unexpected discovery of new gelatin solid or semi-solid dose formulations of nanoparticulate active agents. The new dosage forms comprise a gel-forming substance which exhibits gelation sufficient to retain excess water in the solid or semi-solid gel. [0025] The gelatin solid or semi-solid dose formulations of nanoparticulate active agent compositions comprise at least one nanoparticulate active agent having an effective average particle size of less than about 2000 nm, and at least one surface stabilizer adsorbed on or associated with the surface thereof. The active agent can be poorly soluble in at least one liquid media, such as water. Alternatively, if a nanoparticulate active agent is not poorly soluble, it can be conjugated to a salt or other substance to render the active agent poorly soluble. Thus, agents useful in therapeutic, cosmetic, diagnostic, bioengineering, food, or dietary supplement applications are presumed suitable for the invention. [0026] In addition, the gelatin solid or semi-solid dose nanoparticulate active agent formulations comprise at least one gel forming substance, which provides an active agent dosage form having ease of administration, improved stability of the active agent, and improved dissolution. The gelatm solid or semi-solid dose formulation also exhibits increased redispersion of the component active agent, which achieves pharmaceutically acceptable bioavailability. [0027] Another aspect of the invention is directed to pharmaceutical compositions comprising a nanoparticulate active agent composition of the invention. The pharmaceutical compositions preferably comprise at least one active agent, at least one surface stabilizer, at least one gel forming substance, and at least one pharmaceutically acceptable carrier, as well as any desired excipients. [0028] In another aspect of the invention there is provided a method of preparing gelatin nanoparticulate solid or semi-solid dose formulations. The method comprises: (1) forming a nanoparticulate active agent composition comprising at least one active agent and at least one surface stabilizer; (2) mixing the nanoparticulate active agent composition with melted gelatin, and (3) forming a solid dose form of the composition for administration. The method does not comprise solubilizing the active agent. Additional pharmaceutically acceptable excipients can also be added to the composition for administration. [0029] Yet another aspect of the present invention provides a method of treating a subject, including a human, comprising admimstering a solid or semi-solid gelatin nanoparticulate active agent formulation of the invention, wherein the gelatin formulation exhibits gelation sufficient to retain excess water. [0030] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE FIGURES [0031] Figure 1 : Shows the blood levels of ketoprofen over a 4 hour time period following oral administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate ketoprofen oral gelatin formulation; (b) a 20% nanoparticulate ketoprofen oral gelatin formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle Laboratories (a Division, of American CyanamidGo., Pearl River, NY)). The surface stabilizers in formulations (a)-(c) are polyvinylpyrrolidone (PVP) k29/32 and sodium lauryl sulfate (SLS). [0032] Figure 2: Shows the blood levels of ketoprofen at 10 min., 15 min., 20 min., and 30 min. following oral administration of four different 50 mg ketoprofen dosage formulations: (a) a 20% nanoparticulate gelatin ketoprofen formulation; (b) a 5% nanoparticulate gelatin ketoprofen formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle). The surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS. [0033] Figure 3 : Shows the blood levels of ketoprofen over a 4 hour time period following buccal administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate gelatin ketoprofen formulation; (b) a 20% nanoparticulate gelatin ketoprofen formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle). The surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS. [0034] Figure 4: Shows the blood levels of ketoprofen at 10 min., 15 min., 20 min., and 30 min. following buccal administration of four different 50 mg ketoprofen dosage formulations: (a) a 5% nanoparticulate ketoprofen gelatin formulation; (b) a 20% nanoparticulate ketoprofen gelatin formulation; (c) a nanoparticulate ketoprofen liquid dispersion formulation; and (d) a commercial dose of conventional ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle). The surface stabilizers in formulations (a)-(c) are PVP k29/32 and SLS.
DETAILED DESCRIPTION OF THE INVENTION
[0035] This invention is directed to the surprising and unexpected discovery of a new solid or semi-solid gelatin dosage form. [0036] The solid or semi-solid gelatin nanoparticulate active agent formulations of the invention comprise at least one nanoparticulate active agent to be administered having an effective average particle size prior to inclusion in the dosage form of less than about 2000 nm, at least one surface stabilizer adsorbed on or associated with the surface of the active agent, and at least one gel forming substance which exhibits gelation sufficient to retain excess water in a solid or semi-solid form, thereby achieving redisperability of the active agent. Such redispersibility can result in improved bioavailability of the active agent. [0037] Prior to the present invention, while gelatin dosage forms were desirable, there was an inherent conflict in desiring more water in the dosage form to increase redispersion of the active agent, and knowing that the presence of a significant percentage of water. can result in degradation of the active agent to be delivered. It was unexpectedly discovered that the presence of water does not destabilize or degrade the nanoparticulate active agent in the dosage forms of the invention. [0038] The gelatin dosage forms of the present invention, which retain excess water, disperse and essentially melt upon administration. The amount of water retained by the gel formulation of the invention is at least the amount required to provide for redispersabihty of the nanoparticulate active agent particles upon administration. This equates to a water content of from about 5% to about 97%, from about 20% to about 95%, from about 30% to about 92%o, from about 45% to about 90%o, or from about 65% to about 85%, based on the total weight of the composition. [0039] Benefits of the gelatin dosage form of the invention can include, but are not limited to: (1) rapid delivery of the active agent, which can correlate with rapid active agent absorption; (2) stability of the active agent, which can include particle size and chemical stability of the active agent; (3) excellent redispersabihty of the active agent upon administration or in a biorelevant media; (4) improved bioavailability of the active agent as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (5) a more consistent bioavailability profile for the active agent, aiding in dosage determination, due to the more consistent active agent particle sizes present in the gelatin dosage form, as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (6) the gelatin dosage form is easily administered, requires minimal chewing, rapidly dissolves, and essentially melts at body temperature; (7) the gelatin dosage form can be formulated to mask the unpleasant taste of an active agent; (8) the gelatin dosage form is particularly useful for infant, pediatric, and elderly patient populations, as well as other patient populations which have difficulty in swallowing pills or other solid dosage forms; (9) better patient compliance as the gelatin dosage form is easier to consume and digest as compared to conventional solid dose forms, such as tablets; (10) the gelatin dosage form of the invention does not require potentially toxic solubilizing agents for the active agent; (11) smaller dosage volume as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (12) higher dose loading as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (13) smaller doses of active agent required to obtain the same pharmacological effect as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage, which can correlate with a decrease in toxicity of the active agent; (14) improved pharmacokinetic profiles as compared to a microparticulate or solubihzed form of the same active agent, administered at the same dosage; (15) substantially similar and/or bioequivalent pharmacokinetic profiles of the nanoparticulate active agent compositions when administered in the fed versus the fasted state; (16) bioadhesive gelatin dosage forms of nanoparticulate active agents; and (17) the gelatin dosage forms of the invention can also comprise microparticulate and/or solubihzed active agents, in combination with the nanoparticulate active agent. [0040] The present invention is described herein using several definitions, as set forth below and throughout the application. [0041] As used herein, "about" will be understood by persons of ordinary skill in the art and will vary to some extent on the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art given the context in which it is used, "about" will mean up to plus or minus 10% of the particular term. [0042] "Conventional active agents or drugs" refers to non-nanop articulate or solubihzed active agents or drugs. Non-nanoparticulate active agents have an effective average particle size of greater than about 2 microns. [0043] "Poorly soluble active agents" as used herein means those having a solubility in at least one liquid media of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, or preferably less than about 1 mg/ml, under ambient temperature. Poorly water soluble active agents tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation. [0044] As used herein with reference to stable active agent particles, "stable" includes, but is not limited to, one or more of the following parameters: (1) the active agent particles are substantially chemically, stable, as measured by degradent concentrations; (2) the active agent particles do not appreciably flocculate or agglomerate due to interparticle attractive forces or otherwise increase in particle size over time; (3) the physical structure of the active agent particles is not altered over time, such as by conversion from an amorphous phase to crystalline phase; (4) where the active agent has not been subjected to a heating step at or above the melting point of the active agent in the preparation of the nanoparticles of the invention. [0045] "TherapeuticaUy effective amount" as used herein with respect to an active agent dosage, shall mean the dosage that provides the specific pharmacological response for which the active agent is administered in a significant number of subjects in need of such treatment. It is emphasized that 'therapeuticaUy effective amount,' administered to a particular subject in a particular instance will not always be effective in treating the diseases described herein, even though such dosage is deemed a "therapeuticaUy effective amount" by those skilled in the art. It is to be further understood that active agent dosages are, in particular instances, measured as oral dosages, or with reference to drug levels as measured in blood.
I. Exemplary Preferred Characteristics of the Gelatin Dosage Forms of the Invention A. Redispersibility Profiles of the Gelatm Dosage Forms
[0046] The solid or semi-solid nanoparticulate active agent gelatin dosage forms of the invention exhibit gelation sufficient to retain excess water in the solid or semi-solid active agent dosage form, which provides for rapid redispersion of the active agent. Such rapid redispersion can preferably correlate with increased bioavailability of the active agent. This is significant because previous gelatin formulations failed to contain water, or sufficient amounts of water, because of stability considerations. When insufficient water is present in a gelatin dosage form, the active agent is not sufficiently dissolved and absorbed into the blood stream following administration because there is little or no redispersabihty of the active agent in vivo. [0047] The solid or semi-solid nanoparticulate active agent gelatin dosage forms of the invention preferably redisperse such that the effective average particle size of the redispersed active agent particles is less than about 2 microns. This is significant, as if upon administration the nanoparticulate active agent compositions of the invention did not redisperse to a substantially nanoparticulate particle size, then the gelatin dosage form may lose the benefits afforded by formulating the active agent into a nanoparticulate particle size. [0048] This is because nanoparticulate active agent compositions benefit from the small particle size of the active agent; if the active agent does not redisperse into the small particle sizes upon administration, then "clumps" or agglomerated active agent particles are formed, owing to the extremely high surface free energy of the nanoparticulate active agent system and the thermodynamic driving force to achieve an overall reduction in free energy. With the formation of such agglomerated particles, the bioavailability of the dosage form may fall well below that observed with a form of the nanoparticulate active agent that does not form such agglomerated particles. [0049] Moreover, the gelatin dosage forms of the invention preferably exhibit dramatic redispersion of the component nanoparticulate active agent particles upon administration to a mammal, such as a human or animal, as demonstrated by reconstitution redispersion in a biorelevant aqueous media such that the effective average particle size of the redispersed active agent particles is less than about 2 microns. Such biorelevant aqueous media can be any aqueous media that exhibit the desired ionic strength and pH, which form the basis for the biorelevance of the media. The desired pH and ionic strength are those that are representative of physiological conditions found in the human body. Such biorelevant aqueous media can be, for example, aqueous electrolyte solutions or aqueous solutions of any salt, acid, or base, or a combination thereof, which exhibit the desired pH and ionic strength. [0050] Biorelevant pH is well known in the art. For example, in the stomach, the pH ranges from slightly less than 2 (but typically greater than 1) up to 4 or 5. In the small intestine the pH can range from 4 to 6, and in the colon it can range from 6 to 8. Biorelevant ionic strength is also well known, in the art. Fasted state gastric fluid has an ionic strength of about 0J M while fasted state intestinal fluid has an ionic strength of about 0J4. See e.g., Lindahl et al, "Characterization of Fluids from the Stomach and Proximal Jejunum in Men and Women," Pharm. Res., 14 (4): 497-502 (1997). [0051] It is believed that the pH and ionic strength of the test solution is more critical than the specific chemical content. Accordingly, appropriate pH and ionic strength values can be obtained through numerous combinations of strong acids, strong bases, salts, single or multiple conjugate acid-base pairs (i.e., weak acids and corresponding salts of that acid), monoprotic and polyprotic electrolytes, etc. [0052] Representative electrolyte solutions can be, but are not limited to, HCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and NaCl solutions, ranging in concentration from about 0.001 to about 0.1 M, and mixtures thereof. For example, electrolyte solutions can be, but are not limited to, about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.1 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof. Of these electrolyte solutions, 0.01 M HCl and/or OJ M NaCl, are most representative of fasted human physiological conditions, owing to the pH and ionic strength conditions of the proximal gastrointestinal tract. [0053] Electrolyte concentrations of 0.001 M HCl, 0.01 M HCl, and 0J M HCl correspond to pH 3, pH 2, and pH 1, respectively. Thus, a 0.01 M HCl solution simulates typical acidic conditions found in the stomach. A solution of 0J M NaCl provides a reasonable approximation of the ionic strength conditions found throughout the body, including the gastrointestinal fluids, although concentrations higher than 0J M may be employed to simulate fed conditions within the human GI tract. [0054] Exemplary solutions of salts, acids, bases or combinations thereof, which exhibit the desired pH and ionic strength, include but are not limited to phosphoric acid/phosphate salts + sodium, potassium and calcium salts of chloride, acetic acid/acetate salts + sodium, potassium and calcium salts of chloride, carbonic acid/bicarbonate salts + sodium, potassium and calcium salts of chloride, and citric acid/citrate salts + sodium, potassium and calcium salts of chloride. [0055] In other embodiments of the invention, the redispersed active agent particles of the invention (redispersed in an aqueous, biorelevant, or any other suitable media) have an effective average particle size of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods, microscopy, or other appropriate methods. [0056] Redispersibility can be tested using any suitable means known in the art. See e.g., the example sections of U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate." Exemplary redispersion media includes, but is not limited to, sterile water for injection, saline, dextrose, Lactated Ringer's solution, and Ringers solution. B. Improved Bioavailability [0057] An advantage typically associated with the solid or semi-solid gelatin dosage forms of the invention is a reduction of the time lag between administration of a dose and the physical presentation of the active agent. This lag time is usually associated with the break up of the dosage form and the distribution of the active agent thereafter. [0058] A second advantage of the solid or semi-solid gelatin dosage forms is that the gelatin melts at body temperature. Thus, upon administration, the active agent may be absorbed buccally directly into the blood stream, thus reducing the first pass effect of the liver on the overall bioavailability of active agent from a unit dose. This second advantage is enhanced because the incorporation of the nanoparticulate size of the active agent into the solid or semi-solid gelatin formulations of the invention enables rapid dissolution in the oral cavity. [0059] This combination of rapid delivery, stability, and improved redispersabihty preferably can achieve increased bioavailability of the active agent as compared to prior known gelatin-containing active agent delivery systems. Surprisingly, the gelatin dosage forms of the invention are also superior to nanoparticulate active agent dispersions of the same active agent. This is particularly unexpected as generally liquid dosage forms have greater bioavailability and faster onset of action as compared to sohd or semi-solid dosage forms. [0060] In addition, the gelatin dosage forms of the invention may provide a more consistent bioavailability profile, which aids in dosage determination, as the gelatin dosage forms of the invention preferably have a narrow active agent particle size range. Gelatin dosage forms having highly variable active agent particle sizes, including large crystals, can result in a variable bioavailability profile from dose to dose because smaller particles dissolve faster than the larger aggregates or larger crystal particles. For active agents having a dissolution-rate limited bioavailability, such as poorly water soluble active agents, a faster rate of dissolution is associated with greater bioavailability and a slower rate of dissolution is associated with a lower bioavailability. In such cases, bioavailability is related to the surface area of an administered active agent and, therefore, bioavailability increases with a reduction in the particle size of the dispersed agent. With a composition having widely varying particle sizes, bioavailability becomes highly variable and inconsistent and dosage determinations become difficult. This can be particularly problematic for active agents having a narrow preferred dosage range, such as immunosuppressants, chemotherapy agents, etc. [0061] Finally, the gelatin dosage forms of nanoparticulate active agents of the invention preferably exhibit increased bioavailability, at the same dose of the same active agent, require smaller doses, and show longer plasma half-life as compared to prior conventional active agent formulations.
C. Decreased Active Agent Dosage, Toxicity, and Dosage Volume, and Increased Active Agent Dose Loading
[0062] In another aspect of the invention, the gelatin dosage forms of nanoparticulate active agents of the invention may have enhanced bioavailability such that the active agent dosage can be reduced as compared to a conventional nbn-nanoparticulate dosage form of the same active agent, which can result in a decrease in toxicity associated with the active agent. [0063] In addition, greater bioavailability of the gelatin dosage forms of nanoparticulate active agents of the invention can enable a smaller active agent dosage volume. This is particularly significant for patient populations such as the elderly, juvenile, and infant. [0064] The gelatin dosage forms of the invention can be formulated for dosages in any volume, but are preferably formulated into equivalent or smaller volumes than existing conventional dosage forms of the same active agent (i.e., non-nanoparticulate or solubihzed active agent formulations). For example, the invention encompasses gelatin dosage forms formulated into a volume which is at least half that of a conventional non-nanoparticulate dosage form of the same active agent. Even smaller dosage volumes are also possible. [0065] The maximal dose loading of the gelatin dosage forms of the invention is significantly higher than the maximal dose loading provided by conventional formulations of the same active agents. A dose loading which is double or more than that utilized in conventional, non-nanoparticulate dosage forms of the same active agent is expected to be useful.
D. The Gelatin Dosage Form Does not Require Potentially Toxic Solubilizing Agents for the Active Agent
[0066] Preparation of the solid or semi-solid oral gelatin dosage form does not require solubilizing the active agent. This is significant, as prior art gelatin dosage forms required solubilization of the active agent. Such solubilization of an active agent is undesirable, as it can change the pharmacokinetic and pharmacologic characteristics of the active agent. For example, solubilization followed by precipitation of an active agent can result in a modification of the solidification state of the active agent (i.e., whether the active agent is in an amorphous or crystalline form), it can affect the stability of the active agent in the aqueous state, and it can affect how much of the active agent has returned to the solid state.
E. The Gelatin Dosage Forms of the Invention are Useful for Treating Particular Patient Populations [0067] Because of their ease of administration, compositions according to the present invention are particularly useful for the specific needs of pediatrics, geriatrics, and patients with dysphagia as well as patients with chronic dosing needs. Solid or semi-solid gelatin active agent delivery formulations are beneficial because of their ease of administration, convenience, and patient-friendly nature. It is estimated that 35% to 50% of the population finds it difficult to swallow tablets and hard gelatin capsules, particularly pediatric and geriatric patients. Solid or semi-solid gelatin active agent delivery formulations of the invention eliminate the need to swallow a tablet or capsule whole, as the dosage form "melts" upon administration. [0068] One of the contemplated uses of the solid or semi-solid gelatin nanoparticulate active agent formulations is for pediatric patients. In formulating the gelatin pharmaceutical dosage formulation, the ability to mold the gelatin into shapes such as those that are pleasing and/or entertaining, including but not limited to, animals, letters, numbers, geometric shapes, characters, etc., is particularly useful for administration to young patients. F. Improved Pharmacokinetic Profiles [0069] The invention also preferably provides gelatin dosage forms of nanoparticulate active agents having a desirable pharmacokinetic profile when administered to mammalian subjects. The desirable pharmacokinetic profile of the gelatin dosage forms preferably includes, but is not limited to: (1) that the Tmax of an active agent when assayed in the plasma of a mammalian subject following administration is preferably less than the Traax for a conventional, non-nanoparticulate form of the same active agent, administered at the same dosage; (2) that the Cmax of an active agent when assayed in the plasma of a mammalian subject following administration is preferably greater than the Craax for a conventional, non- nanoparticulate form of the same active agent, administered at the same dosage; and/or (3) that the AUC of an active agent when assayed in the plasma of a mammalian subject following administration, is preferably greater than the AUC for a conventional, non- nanoparticulate form of the same active agent, administered at the same dosage. [0070] The desirable pharmacokinetic profile, as used herein, is the pharmacokinetic profile measured after the initial dose of an active agent. The compositions can be formulated in any way as described herein and as known to those of skill in the art. [0071] A preferred gelatin dosage form of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, a Tmax not greater than about 90%>, not greater than about
80%), not greater than about 70%>, not greater than about 60%, not greater than about 50%, not greater than about 30%, not greater than about 25%, not greater than about 20%, not greater than about 15 ), or not greater than about 10%> of the Tmax, exhibited by the non- nanoparticulate formulation of the same active agent. [0072] A preferred gelatin dosage form of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, a Cmax which is at least about 10%, at least about 20%), at least about 30%>, at least about 40%, at least about 50%, at least about 60%o, at least about 70%), at least about 80%, at least about 90%, or at least about 100% greater than the Cmax exhibited by the non-nanoparticulate formulation of the same active agent. [0073] A preferred gelatin dosage composition of the invention exhibits in comparative pharmacokinetic testing with a non-nanoparticulate formulation of the same active agent, administered at the same dosage, an AUC which is at least about 10%, at least about 20%), at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%), at least about 80%, at least about 90%, or at least about 100% greater than the AUC exhibited by the non-nanoparticulate formulation of the same active agent.
G. Gelatin Dosage Forms Having Combination Pharmacokinetic Profiles [0074] In yet another embodiment of the invention, the gelatin dosage forms of the invention can comprise multiple nanoparticulate active agent compositions of either the same or different active agents. Where the active agent is the same, the compositions can differ in, for example, the active agent particle size or the active agent dosage. In addition, the gelatin dosage form can comprise one or more solubihzed or conventional microparticulate particle size active agents. [0075] For example, the gelatin dosage form can comprise a first nanoparticulate active agent composition having a nanoparticulate particle size, conferring a short Tm and typically a higher Cmax. This first nanoparticulate active agent composition can be combined with a second composition comprising: (1) the same active agent having a larger (but still nanoparticulate as defined herein) particle size, and therefore exhibiting slower absorption, a longer Tmax, and typically a lower Cmax; (2) the same active agent having a microparticulate particle size or which is solubihzed, exhibiting a longer T-^, and typically a lower C^ and/or (3) a different active agent having nanoparticulate particle size, microparticulate particle size, or which is solubihzed. [0076] The second, third, fourth, etc., active agent compositions can differ from the first, and from each other, for example: (1) in the effective average particle sizes of the active agent; (2) the dosage of the active agent; or (3) in the identity of the active agent. Such a combination composition can reduce the dose frequency required. [0077] If the second active agent composition has a nanoparticulate particle size, then preferably the active agent particles of the second composition have at least one surface stabilizer associated with the surface of the active agent particles. The one or more surface stabilizers can be the same as or different from the surface stabilizer(s) present in the first active agent composition. [0078] In another aspect of the invention, nanoparticulate active agent particles can be combined with the microparticulate particles of the same active agent to provide for a gelatin dosage form exhibiting sustained or controlled release. The combination of very small active agent particles, i.e., nanoparticulate active agent particles, in combination with larger active agent particles, i.e., micronized active agent particles, can enable obtaining the simultaneous presentation of immediate-release (IR) and controlled-release (CR) active agent components. For the purposes of this invention, "nanoparticulate" active agents have an effective average particle size of less than about 2 microns and micronized active agents have an effective average particle size of greater than about 2 microns. [0079] The nanoparticulate active agent particles, representing the IR component, afford rapid in vivo dissolution, owing to their small size and attendant large specific surface. Alternatively, micronized active agent particles, representing the CR component, afford slower in vivo dissolution, owing to a comparatively large particle size and small attendant specific surface. [0080] IR and CR components representing a wide range of in vivo dissolution rates (and hence, in vivo input rates for absorption) can be engineered through precise control of active agent particle size. Thus, the compositions can comprise a mixture of nanoparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate, and the compositions can comprise a mixture of microparticulate active agent particles, wherein each population of particles has a defined size correlating with a precise release rate.
H. The Pharmacokinetic Profiles of the Active Agent Compositions of the Invention are not Affected by the Fed or Fasted State of the Subject Ingesting the Compositions [0081] The invention encompasses a gelatin dosage form of a nanoparticulate active agent wherein the pharmacokinetic profile of the active agent is preferably not substantially affected by the fed or fasted state of a subject ingesting the composition, when administered to a human. This means that there is no substantial difference in the quantity of active agent absorbed or the rate of active agent absorption when the gelatin dosage forms are administered in the fed versus the fasted state. [0082] The invention also encompasses a gelatin dosage form of a nanoparticulate active agent in which administration of the gelatm dosage form to a subject in a fasted state is bioequivalent to administration of the gelatin dosage form to a subject in a fed state. "Bioequivalency" is preferably established by a 90% Confidence Interval (CI) of between 0.80 and 1.25 for both Cmax and AUC under U.S. Food and Drug Administration regulatory guidelines, or a 90% CI for AUC of between 0.80 to 1.25 and a 90% CI for Cmax of between 0.70 to 1.43 under the European EMEA regulatory guidelines (T^ is not relevant for bioequivalency determinations under USFDA and EMEA regulatory guidelines). [0083] Benefits of a dosage form which substantially eliminates the effect of food include an increase in subject convenience, thereby increasing subject compliance, as the subject does not need to ensure that they are taking a dose either with or without food. This is significant, as with poor subject compliance an increase in the medical condition for which the active agent is being prescribed may be observed. [0084] The difference in absorption of the gelatin dosage forms of the invention, when administered in the fed versus the fasted state, preferably is less than about 100%, less than about 90%, less than about 80%, less than about 70%, less than about 60%, less than about 50%>, less than about 40%, less than about 30%, less than about 25%o, less than about 20%), less than about 15%, less than about 10%, less than about 5%, or less than about 3%. I. Bioadhesive Gelatin Dosage Forms of Nanoparticulate Active Agents
[0085] Bioadhesive gelatin dosage forms of nanoparticulate active agents according to the present invention comprise at least one cationic surface stabilizer, which are described in more detail below. Bioadhesive gelatin dosage forms of nanoparticulate active agents A. Active Agents [0091] The invention can be practiced with a wide variety of active agents. The active agent is preferably poorly soluble and dispersible in at least one liquid media. Useful liquid dispersion medias include, but are not limited to, water, aqueous salt solutions, safflower oil, and solvents such as ethanol, t-butanol, hexane, and glycol. By "poorly soluble" it is meant that the active agent has a solubility in the liquid dispersion media of less than about 30 mg/ml, preferably less than about 20 mg/ml, preferably less than about 10 mg/ml, and more preferably less than about 1 mg/ml. Two or more active agents can be used in combination. [0092] If an active agent is not poorly soluble, it can be conjugated to a salt or other substance to render the active agent poorly soluble. Thus, active agents having, for example, therapeutic, cosmetic, diagnostic, or bioengineering uses are presumed suitable for the invention. [0093] The active agent may be present either substantially in the form of one optically pure enantiomer or as a mixture, racemic or otherwise, of enantiomers. In addition, the active agent may be in a crystalline form, semi-crystalline form, amorphous form, semi- amorphous form, or a combination thereof. [0094] The active agent can be selected from a variety of known classes of drugs, including, for example, COX-2 inhibitors, retinoids, anticancer agents, NSATDS, proteins, peptides, nucleotides, anti-obesity drugs, nutraceuticals, dietary supplements, carotenoids, corticosteroids, elastase inhibitors, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antiMstamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives (hypnotics and neuroleptics), astringents, beta- adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, corticosteroids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkinsonian agents), haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio- pharmaceuticals, sex hormones (including steroids), anti-allergic agents, stimulants and exhibit exceptional bioadhesion to biological surfaces, such as mucous. The term bioadhesion refers to any attractive interaction between two biological surfaces or between a biological and a synthetic surface. In the case of bioadhesive nanoparticulate active agents, the term bioadhesion is used to describe the adhesion between the nanoparticulate active agents and a biological substrate (i.e. gastrointestinal mucin, lung tissue, nasal mucosa, etc.). See e.g., U.S. Patent No. 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers," which is specifically incorporated by reference. [0086] The bioadhesive gelatin dosage forms of nanoparticulate active agents of the invention are useful in any situation in which it is desirable to apply the compositions to a biological surface. The bioadhesive gelatin dosage forms coat the targeted surface in a continuous and uniform film which is invisible to the naked human eye. [0087] A bioadhesive gelatin dosage form of a nanoparticulate active agent slows the transit of the dosage form, and some active agent particles would also most likely adhere to tissue other than the mucous cells and therefore give a prolonged exposure to the active agent, thereby increasing absorption and the bioavailability of the administered dosage.
II. Compositions
[0088] The starting nanoparticulate active agent composition, prior to formulation into a solid or semi-solid gelatin dosage form, comprises at least one active agent having an effective average particle size of less than about 2 microns and at least one surface stabilizer adsorbed on or associated with the surface of the active agent. [0089] Surface stabilizers useful herein physically adhere on, or associate with, the surface of the nanoparticulate active agent but do not chemically react with the active agent particles or itself. Individual molecules of the surface stabilizer are preferably essentially free of intermolecular cross-linkages. [0090] The present invention also includes gel-stabilized nanoparticulate active agent compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers. The compositions can be formulated for administration in solid or semi-solid form. anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, alpha-hydroxy formulations, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, and respiratory illness therapies associated with acquired immune deficiency syndrome. [0095] Examples of representative active agents useful in this invention include, but are not limited to, acyclovir, alprazolam, altretamine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin, cisapride, clarithromycin, clonidine, clopidogrel, cyclobenzaprine, cyproheptadine, delavirdine, desmopressin, diltiazem, dipyridamole, dolasetron, enalapril maleate, enalaprilat, famotidine, felodipine, furazolidone, glipizide, irbesartan, ketoconazole, lansoprazole, loratadine, loxapine, mebendazole, mercaptopurine, mihinone lactate, minocycline, mitoxantrone, nelfinavir mesylate, nimodipine, norfloxacin, olanzapine, omeprazole, penciclovir, pimozide, tacolimus, quazepam, raloxifene, rifabutin, rifampin, risperidone, rizatriptan, saquinavir, sertraline, sildenafil, acetyl-sulfisoxazole, temazepam, thiabendazole, thioguanine, trandolapril, triamterene, trimetrexate, troglitazone, trovafloxacin, verapamil, vinblastine sulfate, mycophenolate, atovaquone, atovaquone, proguanil, ceftazidime, ' cefuroxime, etoposide, terbinafine, thalidomide, fluconazole, amsacrine, dacarbazine, teniposide, and acetylsalicylate. [0096] Exemplary nutraceuticals and dietary supplements are disclosed, for example, in Roberts et al., Nutraceuticals: The Complete Encyclopedia of Supplements, Herbs, Vitamins, and Healing Foods (American Nutraceutical Association, 2001), which is specifically incorporated by reference. A nutraceutical or dietary supplement, also known [0097] as phytochemicals or functional foods, is generally any one of a class of dietary supplements, vitamins, minerals, herbs, or healing foods that have medical or pharmaceutical effects on the body. Exemplary nutraceuticals or dietary supplements include, but are not limited to, lutein, folic acid, fatty acids (e.g., DHA and ARA), fruit and vegetable extracts, vitamin and mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids (e.g., iso- leucine, leucine, lysine, methionine, phenylanine, threonine, tryptophan, and valine), green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics. Nutraceuticals and dietary supplements also include bio-engineered foods genetically engineered to have a desired property, also known as "pharmafoods." [0098] A description of these classes of active agents and a listing of species within each class can be found in Martindale, The Extra Pharmacopoeia, Twenty-ninth Edition (The Pharmaceutical Press, London, 1989), specifically incorporated by reference. The active agents are commercially available and/or can be prepared by techniques known in the art.
B. Surface Stabilizers [0099] The choice of a surface stabilizer is non-trivial and usually requires extensive experimentation to realize a desirable formulation. [0100] Exemplary useful surface stabilizers include, but are not limited to, known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Exemplary surface stabilizers include nonionic, anionic, cationic, ionic, and zwitterionic surfactants. Combinations of more than one surface stabilizer can be used in the invention. [0101] Representative examples of surface stabilizers include hydroxypropyl methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, random copolymers of vinyl pyrrolidone and vinyl acetate, sodium lauryl sulfate, dioctylsulfosuccinate, gelatin, casein, lecithin (phosphatides), dextran, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Speciality Chemicals)); polyethylene glycols (e.g., Carbowaxs 3550® and 934® (Union Carbide)), polyoxyethylene stearates, colloidal silicon dioxide, phosphates, carboxymethylcellulose calcium, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminium silicate, triethanolamine, polyvinyl alcohol (PVA), 4-(l, 1,3,3- tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol, superione, and triton), poloxamers (e.g., Pluronics F68® and F108®, which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Wyandotte Corporation, Parsippany, N.J.)); Tetronic 1508® (T-l 508) (BASF Wyandotte Corporation), Tritons X-200®, which is an alkyl aryl polyether sulfonate (Rohm and Haas); Crodestas F-110®, which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-IOG® or Surfactant 10-G® (Olin Chemicals, Stamford, CT); Crodestas SL-40® (Croda, Inc.); and SA9OHCO, which is Ci8H37CH2C(O)N(CH3)-CH2(CHOH)4(CH20H)2 (Eastman Kodak Co.); decanoyl-N- methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D-maltopyranoside; n-dodecyl β- D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl-β-D- glucopyranoside; n-heptyl β-D-thioglucoside; n-hexyl β-D-glucopyranoside; nonanoyl-N- methylglucamide; n-noyl β-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D- glucopyranoside; octyl β-D-thioglucopyranoside; PEG-phospholipid, PEG-cholesterol, PEG- cholesterol derivative, PEG- vitamin A, PEG-vitamin E, lysozyme, random copolymers of vinyl pyrrolidone and vinyl acetate, and the like. [0102] Examples of useful cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, poly lysine, polyvinylimidazole, polybrene, polymethylmethacrylate Iximethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrohdone-2-dimethylaminoethyl methacrylate dimethyl sulfate. [0103] Other useful cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammomum chloride, benzyl-di(2-chloroethyl)ethylammomum bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammomum chloride or bromide, decyl triefhyl ammonium chloride, decyl dimethyl hydroxyethyl ammomum chloride or bromide, C12.15dimethyl hydroxyethyl ammomum chloride or bromide, coconut dimethyl hydroxyethyl ammomum chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride or bromide, N-alkyl (C12. lg)dimethylbenzyl ammonium chloride, N-alkyl (C14.18)ώmethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12.14) dimethyl 1-napthylmethyl ammomum chloride, trimethylammonium halide, aU yl-trimethylammonium salts and diaU<yl-dimethylarnmonium salts, lauryl trimethyl ammonium chloride, ethoxylated aU yamidoalkyldialkylammonium salt and/or an ethoxylated trialkyl ammonium salt, dialkylbenzene dialkylammonium chloride, N- didecyldimethyl ammonium chloride, N-tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C12.14) dimethyl 1-naphthylmethyl ammonium chloride and dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammomum chloride, lauryl trimethyl ammomum chloride, alkylbenzyl methyl ammomum chloride, alkyl benzyl dimethyl ammonium bromide, C12, C15, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammonium chloride (DADMAC), dimethyl ammonium chlorides, alkyldimethylammonium halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride (ALIQUAT 336™), POLYQUAT 10™, tetiabutylammonium bromide, benzyl trimethylammonium bromide, choline esters (such as choline esters of fatty acids), benzalkonium chloride, stearalkonium chloride compounds (such as stearyltrimonium chloride and Di- stearyldimonium chloride), cetyl pyridinium bromide or chloride, halide salts of quaternized polyoxyethylalkylamines, MTRAPOL™ and ALKAQUAT™ (Alkaril Chemical Company), alkyl pyridinium salts; amines, such as aUcylamines, dialkylamines, alkanolamines, polyethylenepolyamines, N,N-dialkylaminoalkyl acrylates, and vinyl pyridine, amine salts, such as lauryl amine acetate, stearyl amine acetate, alkylpyridinium salt, and alkylimidazolium salt, and amine oxides; imide azolinium salts; protonated quaternary acrylamides; methylated quaternary polymers, such as poly[diallyl dimethylammonium chloride] and poly-[N-methyl vinyl pyridinium chloride]; and cationic guar. [0104] Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990). [0105] Particularly preferred nonpolymeric primary stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quarternary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammomum compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quarternary ammonium compounds of the formula NRιR2R3R4 (+). For compounds of the formula NRIR2R3R4 (+): (i) none of RrR4 are CH3; (ii) one of RrR4 is CH3; > (iii) three of R R4 are CH3; (iv) all of RrR4 are CH3; (v) two of RrR4 are CH3, one of RrR4 is C6H5CH2, and one of RrR4 is an alkyl chain of seven carbon atoms or less; (vi) two of RΓR4 are CH3, one of R R4 is C6H5CH2, and one of Ri-R4 is an alkyl chain of nineteen carbon atoms or more; (vii) two of R:-R4 are CH3 and one of RrR4 is the group C6H5(CH2)n, where n>l; (viii) two of R R4 are CH3, one of Rj-R4 is C6H5CH2, and one of RrR4 comprises at least one heteroatom; (ix) two of R R4 are CH3, one of RrR4 is C6H5CH2, and one of RrR4 comprises at least one halogen; (x) two of Rt-R4 are CH3, one of Rx-R4 is C6H5CH2, and one of RrR4 comprises at least one cyclic fragment; (xi) ' • two' of Rj-Rψ are CH3 and one of RrR4 is a p'henyl ring; or (xii) two of R.-R4 are CH, and two of RrR4 are purely aliphatic fragments. [0106] Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydro fluoride, chlorallyhnethenamine chloride (Quaternium-15), distearyldimonium chloride (Quaternium-5), dodecyl dimethyl ethylbenzyl ammomum chloride(Quaternium-14), Quaternium-22, Quaternium-26, Quaternium-18 hectorite, dimethylammoethylchloride hydrochloride, cysteine hydrochloride, diethanolammomum POE (10) oletyl ether phosphate, diethanolammomum POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbentonite, stearalkonium chloride, domiphen bromide, denatonium benzoate, myristalkonium chloride, laurtrimonium chloride, ethylenediamine dihydrochloride, guanidine hydrochloride, pyridoxine HCl, iofetarnine hydrochloride, meglumine hydrochloride, methylbenzethonium chloride, myrtrimonium bromide, oleyltrimonium chloride, polyquaternium-1, procainehydrochloride, cocobetaine, stearalkonium bentonite, stearalkoniumhectomte, stearyl trihydroxyethyl propylenediamine dihydrofluoride, tallowtrimonium chloride, and hexadecyltrimethyl ammonium bromide. [0107] Most of these surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference. The surface stabilizers are commercially available and/or can be prepared by techniques known in the art.
C. Particle Size [0108] As used herein, particle size is determined on the basis of the weight average particle size as measured by conventional particle size measuring techniques well known to those skilled in the art. Such techniques include, for example, sedimentation field flow fractionation, photon correlation spectroscopy, light scattering, and disk centrifugation. [0109] By "an effective average particle size of less than about 2000 nm" it is meant that at least about 50%> of the active agent particles have a particle size less than about 2000 nm when measured by the above techniques. In other embodiments of the invention, at least about 70%), at least about 90%>,' at least about 95%>, or at least about 99%> of the active agent particles have a particle size less than the effective average, i.e., less than about 2000 nm. [0110] In other embodiments of the invention, the effective average particle size of the active agent particles is less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm. [0111] In the present invention, the value for D50 of a nanoparticulate active agent composition is the particle size below which 50% of the active agent particles fall, by weight. Similarly, D90 is the particle size below which 90% of the active agent particles fall, by weight. [0112] For conventional or microparticulate active agents, by "an effective average particle size of greater than about 2 microns" it is meant that at least 50%> of the active agent particles have a particle size greater than about 2 microns, when measured by the above techniques.
D. The Gel Forming Substance [0113] The gel forming substance can be a natural, semi-synthetic, or synthetic gelatin, or a chemical or physical gel. At least one natural or synthetic gel forming substance is used in the inventive formulations. [0114] Natural gel forming substances include but are not hmited to algal (e.g., agar, furcelleran, alginate, and carrageenan), botanical (e.g., plant extracts, gum arabic, tragacanth, karaya, ghatti seed gums, guar gum, and locust bean gum), microbial (e.g., xanthan, puUulan, scleroglucan, curdlan, dextran, and gellan), animal (e.g., chitin and chitosan, chrondroitin sulfate, dermatan sulfate, heparain, keratan sulfate, and hyaluroήic acid), and others as described in Park et al., "Biodegradable Hydrogels for Drug Delivery" (Technomic Publishing Company, Inc., 1993). [0115] Synthetic gel forming substances include but are not limited to water-soluble polymers containing complexing groups, which can be crosslmked to form gels. Examples of water-soluble monomers include but are not limited to acrylic acid, methacrylic acid, acrylamide, N-alkylacrylamide, methacrylamide, vinylpyrrolidone, methyl methacrylate, hydroxyethyl methacrylate, and vinyl pyridine which can be crosslinked with, e.g., low molecular weight crosslinking agents, such as N,N'-methylenebisacrylamide and macromolecules, such as proteins. Basically, any molecule with at least two C=C bonds should be able to function as a crosslinking agent in the copolymerization with vinyl monomers and others, as described in "Biodegradable Hydrogels for Drug Delivery".
E. Other Pharmaceutical Excipients [0116] Pharmaceutical compositions according to the invention may also comprise one or more binding agents, filling agents, lubricating agents, suspending agents, sweeteners, flavoring agents, preservatives, buffers, wetting agents, disintegrants, effervescent agents, and other excipients. Such excipients are known in the art. [0117] Because many drugs have an unpleasant taste, the use of taste masking excipients may be added to the gelatin composition to achieve a composition which is pleasant tasting and easily administered. In addition to pleasant tasting flavors, interesting • coloring agents can be added to the formulation. [0118] Such taste masking can be accomplished, for example, by the addition of one or more sweet tasting excipients, by coating the nanoparticulate active agent and one or more surface stabilizers with a sweet tasting excipient, and/or by coating a dosage form of the nanoparticulate active agent, one or more surface stabilizers, and excipients with a sweet tasting excipient. [0119] Examples of filling agents are lactose monohydrate, lactose anhydrous, and various starches; examples of binding agents are various celluloses and cross-linked polyvinylpyrrolidone, microcrystaUine cellulose, such as Avicel® PHI 01 and Avicel® PHI 02, microcrystaUine cellulose, and silicifized microcrystaUine cellulose (SMCC). [0120] Suitable lubricants, including agents that act on the flowability of the powder to be compressed, are colloidal silicon dioxide, such as Aerosil® 200; talc, stearic acid, magnesium stearate, calcium stearate, and silica gel. [0121] Examples of sweeteners are any natural or artificial sweetener, such as sucrose, xylitol, sodium saccharin, cyclamate, aspartame, and acesulfame. Examples of flavoring agents are Magnasweet® (trademark of MAFCO), bubble gum flavor, and fruit flavors, and the like. [0122] Examples of preservatives are potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other .esters of parahydroxybenzbic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quarternary compounds such as benzalkonium chloride. [0123] Suitable diluents include pharmaceutically acceptable inert fillers, such as microcrystaUine cellulose, lactose, dibasic calcium phosphate, saccharides, and/or mixtures of any of the foregoing. Examples of diluents include microcrystaUine cellulose, such as Avicel® PH101 and Avicel® PH102; lactose such as lactose monohydrate, lactose anhydrous, and Pharmatose® DCL21; dibasic calcium phosphate such as Emcompress®; mannitol; starch; sorbitol; sucrose; and glucose. [0124] Suitable disintegrants include lightly crosslinked polyvinyl pyrrolidone, corn starch, potato starch, maize starch, and modified starches, croscarmellose sodium, cross- povidone, sodium starch glycolate, and mixtures thereof. [0125] Examples of effervescent agents are effervescent couples such as an organic acid and a carbonate or bicarbonate. Suitable organic acids include, for example, citric, tartaric, malic, fumaric, adipic, succinic, and alginic acids and anhydrides and acid salts. Suitable carbonates and bicarbonates include, for example, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, magnesium carbonate, sodium glycine carbonate, L-lysine carbonate, and arginine carbonate. Alternatively, only the acid component of the effervescent couple may be present.
F. Quantities of Nanoparticulate Active Agent Composition and Gel forming Substance [0126] The relative amount of nanoparticulate active agent composition in the gelatin dosage forms of the invention can vary widely and can depend upon, for example, the active agent and surface stabilizer(s) selected for delivery, the melting point of the active agent and surface stabilizer, the water solubility of the active agent and surface stabilizer, the surface tension of water solutions of the active agent and surface stabilizer, etc. The active agent may be present in any amount which is sufficient to elicit a therapeutic effect. [0127] The concentration of the at least one active agent can vary from about 99.5%> to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined weight of the active agent and surface stabilizer, not including other excipients. [0128] The concentration of the at least one surface stabilizer can vary from about 0.5% to about 99.999%), from about 5.0% to about 99.9%, and from about 10.0% to about 99.5%o, by weight, based on the total combined dry weight of the active agent and surface stabilizer, not including other excipients. [0129] The at least one gel forming substance can be present in an amount of about 0.5%) to about 60%, about 3% to about 40%>, or about 5%o to about 20%, by weight, based on the total weight of the active agent, surface stabilizer, and gel forming substance.
III. Methods of Making Solid or Semi-Solid Gelatin Nanoparticulate Active Agent Compositions [0130] In another aspect of the invention there is provided a method of preparing solid or semi-solid gelatin dosage forms of nanoparticulate active agents. The method comprises combining: (1) a nanoparticulate active agent composition of at least one active agent and at least one surface stabilizer, wherein the active agent has an effective average particle size of less than about 2000 nm, and (2) at least one gel forming substance, which exhibits gelation sufficient to retain excess water in a solid or semi-solid form, to form a solid dose matrix surrounding the nanoparticulate active agent composition. The method does not comprise solubilizing the active agent. This composition is used to form a solid dose formulation, wherein the gelatin solid dose composition achieves redispersion upon administration to a patient. [0131] Nanoparticulate active agent compositions can be made using, for example, milling, precipitation, or homogenization techniques. Exemplary methods of making nanoparticulate active agent compositions are described in U.S. Patent No. 5,145,684. Methods of making nanoparticulate active agent compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,862,999 for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,543,133 for "Process of Preparing X-Ray Contrast Compositions Containing Nanoparticles;" U.S. Patent No. 5,534,270 for "Method of Preparing Stable Drug Nanoparticles;" U.S. Patent No. 5,510,118 for "Process of Preparing Therapeutic Compositions Containing Nanoparticles;" and U.S. Patent No. 5,470,583 for "Method of Preparing Nanoparticle Compositions Containing Charged Phospholipids to Reduce Aggregation," all of which are specifically incorporated by reference. [0132] In a typical manufacturing process, the solid or semi-solid gelatin nanoparticulate matrix composition is prepared by mixing gelatin at an appropriate concentration and warming the mixture in a water bath, such as at about 50°C. A warmed amount of a nanoparticulate active agent dispersion (comprising at least one active agent and at least one surface stabilizer) is slowly added to the molten gelatin with an overhead mixer and mixed, such as for about 10 minutes. The nanoparticulate active agent dispersion can also be heated in a water bath of about 50°C. Upon completion of mixing, the molten mixture is homogenized. When the homogenization is completed, the formulation is dispensed into a mold and refrigerated until formed. [0133] The gelatin formulations of the invention can be formulated into solid or semi- liquid dosage formulations, such as controlled release formulations, solid dose fast melt formulations, lyophilized formulations, aerosol formulations, tablets, capsules, lozenges, etc.
1. Milling to Obtain Nanoparticulate Active Agent Dispersions 5 [0134] Milling an active agent to obtain a nanoparticulate dispersion for subsequent formulation into a solid or semi-solid gel dosage form comprises dispersing particles of at least one active agent in a liquid dispersion media in which the active agent is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the active agent to the desired effective average particle size. The dispersion
10 media can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol. [0135] The active agent particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the active agent particles can be contacted with one or more surface stabilizers after attrition. Other compounds, such as a diluent, can be added to the
15 active agent/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
2. Homogenization to Obtain Nanoparticulate Active Agent Compositions [0136] Exemplary homogenization methods of preparing active agent nanoparticulate 20. compositions are described in U.S. Patent No. 5,510,118, for "Process of Preparing Therapeutic Compositions Containing Nanoparticles." [0137] Such a method comprises dispersing active agent particles in a liquid dispersion media, followed by subjecting the dispersion to homogenization to reduce the particle size of the active agent to the desired effective average particle size. The active agent 25 particles can be reduced in size in the presence of at least one surface stabilizer. Alternatively, the active agent particles can be contacted with one or more surface stabilizers either before or after particle size reduction. Other compounds, such as a diluent, can be added to the active agent/surface stabilizer composition either before, during, or after the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
30 C. Administration of Solid or Semi-Solid Gelatin Dosage Form of a Nanoparticulate Active Agent [0138] The present invention provides a method of treating a subject, including humans and animals, requiring the rapid availability and ease of administration of an active agent, and in particular a poorly water soluble active agent. The method comprises administering to the subject an effective amount of a solid or semi-solid gelatin dosage form of a nanoparticulate active agent. The gelatin dosage form melts, and the component nanoparticulate active agent particles redisperse, upon administration. [0139] The composition can be formulated into any suitable dosage form, such as a immediate release formulation, controlled release formulation, fast melt formulation, delayed release formulation, extended release formulation, pulsatile release formulation, and mixed immediate release and controlled release formulation. [0140] An alternative method of administration involves administering an effective amount of a solid or semi-solid gelatin dosage form of a nanoparticulate active agent which redisperses upon administration to a fasted patient. A fasted patient is defined as a patient that has not ingested food for a period of time prior to administration of the gelatin dosage form. As shown in the examples below, it was surprisingly discovered that the gelatin dosage forms of the invention have an enhanced efficacy in a fasted patient in comparison to administration of a nanoparticulate active agent dispersion. [0141] In general, the compositions of the invention are administered via any pharmaceutically acceptable method to a subject in need thereof using a level of active agent that is sufficient to provide the desired physiological effect, such as oral, rectal, vaginal, local, buccal, and topical administration. The subject may be a domestic animal or pet but preferably is a human subject. The level of active agent needed to give the desired physiological result is readily determined by one of ordinary skill in the art by referring to standard texts, such as Goodman and Gillman and the Physician's Desk Reference.
[0142] The following examples are given to illustrate the present invention. It should be understood, however, that the invention is not to be limited to the specific conditions or details described in these examples. Throughout the specification, any and all references to publicly available documents are specifically incorporated into this patent application by reference. Example 1 [0143] The purpose of this example was to prepare a nanoparticulate gelatin formulation of Compound A, having analgesic properties. [0144] A nanoparticulate dispersion of Compound A was prepared, comprising 20%> Compound A, 4%> Plasdone® S630 (a copolymer of vinyl pyrrolidone and vinyl acetate from ISP), and 0.8% dioctylsulfosuccinate (DOSS). The dispersion was prepared by milling Compound A, Plasdone® S630, and DOSS with a Dyno®-Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 300 cc recirculation chamber using a 500 μm milling media of type Polymill 500® for 6 hrs at 10°C. [0145] The initial particle size was measured using a Horiba LA-910 Static Light
Scattering Particle Analyzer (Horiba Instruments, Irvine, CA). The mean particle size of Compound A dispersion was 138 nm with a D90 of 202 nm. [0146] The solid gelatin matrix of nanoparticulate Compound A was prepared by warming a 20% gelatin: 80% water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. [0147] Next, the nanoparticulate dispersion of 20% Compound A, 4%> Plasdone® S630, and 0.8% dioctylsulfosuccinate (DOSS) was heated in a 50°C water bath until the dispersion reached 50°C. The dispersion was slowly added to the molten gelatin in a 1 : 1 ratio (nanoparticulate Compound A dispersion: gelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate Compound A dispersion had the following composition: 10%> Compound A, 2% Plasdone® S630, 0.4%ι dioctylsulfosuccinate (DOSS), and 10%> gelatin with the remaining 77.6%o of the composition being water. [0148] Upon completion of mixing, a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, the formulation was dispensed into a mold and refrigerated until formed.
Example 2 [0149] The purpose of this example was to prepare a nanoparticulate Ketoprofen gelatin formulation. Ketoprofen is a well-known nonsteroidal anti-inflammatory agent (NSATD). [0150] A nanoparticulate Ketoprofen dispersion was prepared, comprising 30%> ketoprofen and 3%o polyvinylpyrrolidone (PVP k90). The dispersion was prepared by milling ketoprofen and PVP with a Dyno®-Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 150 cc batch chamber using a 500 μm milling media of type Polymill 500® for 2 hrs at 10°C. [0151] The initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA). The mean particle size of the ketoprofen dispersion was 183 nm, with a D50 and D90 of 178 nm and 249 nm, respectively. [0152] The solid gelatin matrix of nanoparticulate ketoprofen was prepared by wanning a 20%> gelatin: 80%> water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. [0153] A nanoparticulate dispersion of 30%> ketoprofen and 3%> PVP heated in a 50°C water bath until the dispersion reached 50°C. The dispersion was slowly added to the molten gelatin in a 1 J ratio (nanoparticulate ketoprofen dispersion: gelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition; 15% ketoprofen, 1.5%o PVP, and 10% gelatin with the remaining 73.5% of the composition being water. [0154] Upon completion of mixing, a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, the formulation was dispensed into a mold and refrigerated until formed.
Example 3 [0155] The purpose of this example was to compare the redispersion properties of various solid or semi-solid nanoparticulate naproxen gelatin dosage formulations. Naproxen is a well-known anti-inflammatory, analgesic, and antipyretic agent. [0156] A first nanoparticulate dispersion of naproxen was prepared, comprising 20% naproxen and 2% PVP k90. The dispersion was prepared by milling naproxen and PVP with a Dyno®-Mill (Type: KDL; Mfg.: Willy A Bachofen AG, Basel, Switzerland) equipped with a 300 cc batch chamber using a 500 μm milling media of type Polymill 500® for 5 hrs at 10°C. [0157] The initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA). The mean particle size of the first naproxen dispersion was 154 nm, with a D50%> and a D90%> of 145 and 222 nm, respectively. [0158] A second nanoparticulate naproxen dispersion was prepared, comprising 40% naproxen and 4%> PVP k90. The dispersion was prepared by milling naproxen and PVP in a similar manner to the first dispersion. [0159] The initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA). The mean particle size of the second naproxen dispersion was 158 nm, with a D50%> and a D90% of 152 and 216 nm, respectively. [0160] Two gelatin formulations of nanoparticulate naproxen were prepared utilizing the two nanoparticulate naproxen compositions. [0161] The first solid gelatin matrix of nanoparticulate naproxen was prepared by warming a 10% gelatin: 90%o water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. Next, the nanoparticulate dispersion of 20%> naproxen and 2%> PVP was heated in a 50°C water bath until the dispersion reached 50°C. The dispersion was slowly added to the molten gelatin in a 0.25:1 ratio (nanoparticulate naproxen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate naproxen dispersion had the following composition: 4% naproxen, 0.4%> PVP, and 8% gelatin with the remaining 87.6% of the composition being water. [0162] The second solid gelatin matrix of nanoparticulate naproxen was prepared by warming a 30% gelatin: 70% water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. Next, the nanoparticulate naproxen dispersion of 40%o naproxen and 4% PVP was heated in a 50° C water bath until the dispersion reached 50°C. The dispersion was slowly added to the molten gelatin in a 1:0.5 ratio (nanoparticulate naproxen dispersio gelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate naproxen dispersion had the following composition; 26.7% naproxen, 2.7% PVP, and 10%) gelatin with the remaining 60.6% of the composition being water. [0163] Upon completion of mixing, a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, each formulation was dispensed into a mold and refrigerated until formed. [0164] The two gelatin formulations were redispersed in water at 35-40°C. Naproxen particle size following redispersion was measured using a Horiba LA910 particle sizer. The results of the redispersion tests are shown in Table 1, below.
Figure imgf000042_0001
[0165] The results dramatically show the successful redispersion of the nanoparticulate naproxen gelatin formulations.
Example 4 [0166] The purpose of this example was to investigate the redispersibility properties of the semi-solid gelatin nanoparticulate Compound A dosage formulation manufactured according to Example 1. [0167] The composition of the dosage form was 10% Compound A, 2%o Plasdone® S630, 0.4% dioctylsulfosuccinate (DOSS), and 10% gelatin with the remaining 77.6% of the composition being water. r0168] The gelatin formulation was redispersed in Simulated Gastric Fluid (SGF) at
35-40°C. Compound A particle size was measured using a Horiba LA910 particle sizer. The results of the redispersion tests are shown in Table 2, below.
Figure imgf000042_0002
[0169] The results dramatically show the successful redispersion of the nanoparticulate Compound A gelatin formulations.
Example 5 [0170] The purpose of this example was to investigate the redispersibility properties of the semi-solid gelatin nanoparticulate ketoprofen dosage formulation manufactured according to Example 2. [0171] The composition of the dosage form was 15% ketoprofen, 1.5%> PVP, and 10%) gelatin with the remaining 73.5% of the composition being water. [0172] The gelatin formulation was redispersed in water at 35-40°C. Ketoprofen particle size was measured using a Horiba LA910 particle sizer. The results of the redispersion tests in water and simulated gastric fluid (SGF), are shown in Table 3, below.
Figure imgf000044_0001
[0173] The results dramatically show the successful redispersion of the nanoparticulate ketoprofen gelatin formulations.
Example 6 [0174] The purpose of this example was to evaluate the in vivo performance of nanoparticulate ketoprofen gelatin formulations admimstered orally to fasted beagles. [0175] Four ketoprofen formulations were used in the study: (1) commercial ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle), having an approximate particle size of 500 microns; (2) a nanoparticulate ketoprofen dispersion, preparation of which is described below; (3) a 5%> soft oral gelatin formulation, preparation of which is described below; and (4) a 20% hard oral gelatin formulation, preparation of which is described below. [0176] A nanoparticulate dispersion of ketoprofen was prepared, comprising 30%o ketoprofen, 3% PVP k29/32, and 0.15% sodium lauryl sulphate (SLS). The dispersion was prepared by milling ketoprofen, PVP and SLS with a NanoMill®-2 (Mfg.: Netzch, Exton, P.A., U.S.A.) using a 500 μm milling media of type Polymill 500® at 10°C until the desired particle size was achieved. [0177] The initial particle size was measured using a Horiba LA-910 Static Light Scattering Particle Analyzer (Horiba Instruments, Irvine, CA). The mean particle size of the Ketoprofen dispersion was 153 nm, with a D50%> and a D90%> of 148 and 208 nm, respectively. [0178] Two gelatin formulations of nanoparticulate ketoprofen were prepared utilizing the nanoparticulate ketoprofen composition. [0179] The first solid gelatin matrix of nanoparticulate ketoprofen - termed "5% soft oral gelatin formulation," was prepared by warming a 10% gelatin: 90%) water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. Next, the nanoparticulate ketoprofen dispersion of comprising 30% ketoprofen, 3% PVP k29/32, and 0.15% SLS was heated in a 50°C water bath until the dispersion reached 50°C. The warmed ketoprofen dispersion was then slowly added to the molten gelatin in a 1 : 1 ratio (nanoparticulate ketoprofen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition: 10%> ketoprofen, 1% PVP, 0.5% SLS and 5%> gelatin with the remaining 83.5% of the composition being water. [0180] The second solid gelatin matrix of nanoparticulate ketoprofen - termed "20% hard oral gelatin formulation," was prepared by warming a 40% gelatin: 60% water mixture (250 Bloom Type B NF Bone Gelatin manufactured by Kind & Knox, Sioux City, IA) at 50°C in a water bath. Next, the nanoparticulate ketoprofen dispersion of comprising 30% ketoprofen, 3% PVP k29/32, and 0.15% SLS was heated in a 50°C water bath until the dispersion reached 50°C. The warmed ketoprofen dispersion was then slowly added to the molten gelatin in a 1:1 ratio (nanoparticulate ketoprofen dispersiomgelatin solution) with an overhead mixer and mixed for 10 minutes. The resultant gelatin/nanoparticulate ketoprofen dispersion had the following composition: 10% ketoprofen, 1% PVP, 0.5% SLS and 20%) gelatin with the remaining 68.5% of the composition being water. [0181] Upon completion of mixing, a pump was connected and the molten mixture was homogenized at 12000 rpm for approximately 3 minutes. When the homogenization was completed, each formulation was dispensed into a mold and refrigerated until formed. [0182] Twenty dogs were used in the study. (a) 8 dogs were administered commercial ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle), having an approximate particle size of 500 microns. (b) 4 dogs were administered a 50 mg dose of a nanoparticulate crystalline dispersion of ketoprofen (NCD); (c) 4 dogs were administered a 50 mg dose of ketoprofen in a 5%> soft oral gelatin formulation; and (d) 4 dogs were administered a 50 mg dose of ketoprofen in a 20%> hard oral gelatin formulation. [0183] Administration was by oral gavage to the back of the throat, whereby the dogs swallowed the formulations. As determined from Figure 1, the gelatin formulations had a faster onset of action, as the mean peak plasma level concentration (Cmax) of the 5%> gelatin formulation was 17.5 μg/ml at twenty minutes after administration, which corresponds to an onset of action rate as determined from blood plasma levels of 0.85 μg/min. The hard gelatin (20%) gelatin) also provided rapid onset of action and exhibited a Cmax of 19.9 μg/ml, which corresponds to an onset of action rate as determined from blood plasma levels of 1 μg/min. [0184] By comparison, the commercial dosage exhibited a Cmax of 10.6 μg/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.5 μg/min. The NCD performed similarly, exhibiting a Cmax of 11.145 μg/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.52 μg/min. [0185] Figure 2 clearly shows that the soft nanoparticulate gel dosage form (5%> gelatin) initially exhibits the highest blood concentration of ketoprofen, whereas the hard nanoparticulate gel dosage form (20%> gelatin), while exhibiting a slower onset that the soft nanogel, ultimately delivers more ketoprofen from the gelatin.
Example 7 [0186] The purpose of this example was to evaluate the in vivo performance of nanoparticulate ketoprofen gelatin formulations administered bucally to fasted beagles. The ketoprofen formulations used in this study were the same as in example 6. [0187] Twenty dogs were used in the study. (a) 8 dogs were administered commercial ketoprofen (generic ketoprofen 50 mg capsules manufactured by Lederle); (b) 4 dogs were administered a 50 mg dose -of a nanoparticulate crystalline dispersion of ketoprofen (NCD); (c) 4 dogs were administered a 50 mg dose of ketoprofen in a 5% soft oral gelatin formulation; and (d) 4 dogs were administered a 50 mg dose of ketoprofen in a 20%> hard oral gelatin formulation. [0188] Administration was accomplished by placing the dosage under the tongues of the individual dogs and muzzling the dogs to allow for absorption with checking for complete dissolution of the dosage form after 1 minute. [0189] As determined from Figure 3, the gelatin formulations had a faster onset of action, as the mean peak plasma level concentration (Cmax) of the soft gelatin dosage form (5% gelatin) was 14.89 μg/ml at twenty minutes after administration, which corresponds to an onset of action rate as determined from blood plasma levels of 0.75 μg/min. The hard gelatin dosage form (20% gelatin) also provided rapid onset of action and exhibited a Cmax of 15.95 μg/ml, which corresponds to an onset of action rate as determined from blood plasma levels of 0.67 μg/min. [0190] By comparison, the commercial dosage exhibited a Craax of 10.6 μg/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.5 μg/min. The ketoprofen NCD performed similarly, exhibiting a Cmax of 12.37 μg/ml, corresponding to an onset of action rate as determined from blood plasma levels of 0.56 μg/min. [0191] Figure 4 clearly shows that the soft nanoparticulate gel dosage form (5% gelatin) initially exhibits the highest blood concentration of ketoprofen, whereas the hard nanoparticulate gel dosage form (20%> nanogel), while exhibiting a slower onset that the soft nanogel, ultimately delivers more ketoprofen from the gelatin.
* * * * [0192] It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.

Claims

WE CLAIM:
1. A solid or semi-solid gelatin composition comprising: (a) at least one active agent having an effective average particle size of less than about 2000 nm prior to inclusion in the composition; (b) at least one surface stabilizer; and (c) at least one gel forming substance, which exhibits gelation sufficient to retain excess water in a solid or semi-solid state.
2. The composition of claim 1, wherein the concentration of the at least one active agent is selected from the group consisting of from about 99.5%> to about 0.001%, from about 95%o to about 0.1%, and from about 90%> to about 0.5%>, by weight, based on the total combined weight of the at least one active agent and at least one surface stabilizer, not including other excipients.
3. The composition of claim 1 or claim 2, wherein the concentration of the at least one surface stabilizer is selected from the group consisting of from about 0.5%o to about 99.999%, from about 5.0% to about 99.9%, and from about 10% to about 99.5%%,, by weight, based on the total combined dry weight of the at least one active agent and at least one surface stabilizer, not including other excipients.
4. The composition of any one of claims 1-3, wherein the concentration of the at least one gel forming substance is selected from the group consisting of from about 0.5% to about 60%, from about 3% to about 40%, and from about 5%, to about 20%, by weight, based on the total weight of the active agent, at least one surface stabilizer, and the at least one gel forming substance.
5. The composition of any one of claims 1-4, wherein the amount of water present in the composition is selected from the group consisting of from about 5% to about 97%, from about 20% to about 95%, from about 30% to about 92%, from about 45% to about 90%,, and from about 65% to about 85%,, based on the total weight of the composition.
6. The composition of any one of claims 1-5, wherein the gel forming substance is selected from the group consisting of a natural gelatin, a semi-syntheic gelatin, and a synthetic gelatin.
7. The composition of claim 6, wherein the gel foπ ing substance is a natural gelatin selected from the group consisting of algal, botanical, microbial, and animal.
8. The composition of claim 7, wherein the gel foπning substance is a natural gelatin selected from the group consisting of agar, furcelleran, alginate, carrageenan, plant extracts, gum arabic, tragacanth, karaya, ghatti seed gums, guar gum, locust bean gum, xanthan, puUulan, scleroglucan, curdlan, dextran, gellan, chitin, chitosan, chrondroitin sulfate, dermatan sulfate, heparain, keratan sulfate, and hyaluronic acid.
9. The composition of claim 6, wherein the gel forming substance is a water- soluble polymer containing complexing groups which is crosslinked to form a gel.
10. The composition of claim 9, wherein the water-soluble polymer is selected from the group consisting of acrylic acid, methacrylic acid, acrylamide, N-alkylacrylamide, methacrylamide, vinylpyrrolidone, methyl methacrylate, hydroxyethyl methacrylate, and vinyl pyridine.
11. The composition of claim 9, wherein the complexing group is selected from the group consisting ofN,N'-methylenebisacrylamide and proteins.
12. The composition of any one of claims 1-11, wherein the effective average particle size of the active agent particles is selected from the group consisting of less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.
13. The composition of any one of claims 1-12, wherein at least about 70%,, at least about 90%, or at least about 95%> of the active agent particles have a particle size less than the effective average particle size.
14. The composition of any one of claims 1-13, wherein the gelatin nanoparticulate composition has been molded into a shape selected from the group consisting of a geometric shape, an animal shape, a numeric shape, a character shape, and an alphabet shape.
15. The composition of any one of claims 1-14, wherein the composition is formulated for administration selected from the group consisting of oral, rectal, vaginal, local, buccal, and topical administration.
16. The composition of any one of claims 1-15, formulated into a dosage form selected from the group consisting of immediate release formulation, controlled release formulation, fast melt formulation, delayed release formulation, extended release formulation, pulsatile release formulation, and mixed immediate release and controlled release formulation.
17. The composition of any one of claims 1-16, wherein the composition further comprises one or more pharmaceutically acceptable excipients, carriers, or a combination thereof.
18. The composition of any one of claims 1-17, wherein the at least one active agent is in the form selected from the group consisting of crystalline particles, semi- crystalline particles, semi-amorphous particles, amorphous particles, and a mixture thereof.
19. The composition of any one of claims 1-18, wherein the at least one active agent is poorly soluble in at least one liquid media, wherein "poorly soluble" is defined as a solubility in the liquid media selected from the group consisting of less than about 30 mg/mL, less than about 20 mg/mL, less than about 10 mg/mL, and less than about 1 mg/mL.
20. The composition of claim 19, wherein the liquid media is selected from the group consisting of water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, and glycol.
21. The composition of any one of claims 1-20, wherein the at least one active agent has been rendered poorly soluble in at least one liquid media by conjugation to a salt or other suitable substance.
22. The composition of any one of claims 1-21, wherein the at least one active agent is selected from the group consisting of COX-2 inhibitors, anticancer agents, NSAIDS, proteins, peptides, nutraceuticals, anti-obesity agents, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiac inotropic agents, contrast media, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio- pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, acne medication, alpha-hydroxy formulations, cystic-fibrosis therapies, asthma therapies, emphysema therapies, respiratory distress syndrome therapies, chronic bronchitis therapies, chronic obstructive pulmonary disease therapies, organ-transplant rejection therapies, therapies for tuberculosis and other infections of the lung, and respiratory illness therapies associated with acquired immune deficiency syndrome.
23. The composition of claim 22, wherein the nutraceutical is selected from the group consisting of dietary supplements, vitamins, minerals, herbs, healing foods that have medical or pharmaceutical effects on the body, folic acid, fatty acids, fruit and vegetable extracts, vitamin supplements, mineral supplements, phosphatidylserine, lipoic acid, melatonin, glucosamine/chondroitin, Aloe Vera, Guggul, glutamine, amino acids, green tea, lycopene, whole foods, food additives, herbs, phytonutrients, antioxidants, flavonoid constituents of fruits, evening primrose oil, flax seeds, fish and marine animal oils, and probiotics.
24. The composition of any one of claims 1-21, wherein the active agent is selected from the group consisting of acyclovir, alprazolam, alfreta nine, amiloride, amiodarone, benztropine mesylate, bupropion, cabergoline, candesartan, cerivastatin, chlorpromazine, ciprofloxacin, cisapride, clarithromycin, clonidine, clopidogrel, cyclobenzaprine, cyproheptadine, delavirdine, desmopressin, diltiazem, dipyridamole, dolasetron, enalapril maleate, enalaprilat, famotidine, felodipine, furazolidone, glipizide, irbesartan, ketoconazole, lansoprazole, loratadine, loxapine, mebendazole, mercaptopurine, milrinone lactate, minocycline, mitoxantrone, nelfinavir mesylate, nimodipine, norfloxacin, olanzapine, omeprazole, penciclovir, pimozide, tacolimus, quazepam, raloxifene, rifabutin, rifampin, risperidone, rizatriptan, saquinavir, sertraline, sildenafil, acetyl-sulfisoxazole, temazepam, thiabendazole, tHoguanine, trandolapril, triamterene, trimetrexate, troghtazone, trovafloxacin, verapamil, vinblastine sulfate, mycophenolate, atovaquone, atovaquone, proguanil, ceftazidime, cefuroxime, etoposide, terbinafine, thalidomide, fluconazole, amsacrine, dacarbazine, teniposide, and acetylsalicylate.
25. The composition of any one of claims 1 -22, wherein the active agent is selected from the group consisting of an analgesic, ketoprofen, and naproxen.
26. The composition of any one of claims 1-25, comprising at least two surface stabilizers.
27. The composition of any one of claims 1-26, wherein the surface stabilizer is selected from the group consisting of an ionic surface stabilizer, an anionic surface stabilizer, a cationic surface stabilizer, a nonionic surface stabilizer, and a zwitterionic surface stabilizer.
28. The composition of any one of claims 1-27, wherein the at least one surface stabilizer is selected from the group consisting of cetyl pyridinium chloride, gelatin, casein, phosphatides, dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, polyethylene glycols, dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses, hypromellose, carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hypromellose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol, polyvinylpyrrolidone, 4- (lJ,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde, poloxamers; poloxamines, a charged phospholipid, dioctylsulfosuccinate, dialkylesters of sodium sulfosuccinic acid, sodium lauryl sulfate, alkyl aryl polyether sulfonates, mixtures of sucrose stearate and sucrose distearate, p-isononylphenoxypoly-(glycidol), decanoyl-N- methylglucamide; n-decyl β-D-glucopyranoside; n-decyl β-D-maltopyranoside; n-dodecyl β- D-glucopyranoside; n-dodecyl β-D-maltoside; heptanoyl-N-methylglucamide; n-heptyl- β-D- glucopyranoside; n-heptyl β-D-thioglucoside; n-hexyl β-D-glucopyranoside; nonanoyl-N- methylglucamide; n-noyl β-D-glucopyranoside; octanoyl-N-methylglucamide; n-octyl-β-D- glucopyranoside; octyl β-D-thioglucopyranoside; lysozyme, PEG-phospholipid, PEG- cholesterol, PEG-cholesterol derivative, PEG- vitamin A, and random copolymers of vinyl acetate and vinyl p.yrrolidone.
29. The composition of claim 27, wherein the at least one cationic surface stabilizer is selected from the group consisting of a polymer, a biopolymer, a polysacchari.de, a cellulosic, an alginate, a nonpolymeric compound, a phospholipid, cationic lipids, polymetliylmethacrylate trimethylammonium bromide, sulfonium compounds, polyvinylpyrrolidone-2-dimethylaminoethyl methacrylate dimethyl sulfate, hexadecyltrimethyl ammonium bromide, phosphonium compounds, quarternary ammonium compounds, benzyl-di(2-cMoroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride, coconut trimethyl ammonium bromide, coconut methyl dihydroxyethyl ammomum chloride, coconut methyl dihydroxyethyl ammonium bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride bromide, C12_15dimethyl hydroxyethyl ammonium chloride, C12- ιsdimethyl hydroxyethyl ammonium chloride bromide, coconut dimethyl hydroxyethyl ammonium chloride, coconut dimethyl hydroxyethyl ammomum bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride, lauryl dimethyl benzyl ammonium bromide, lauryl dimethyl (ethenoxy)4 ammonium chloride, lauryl dimethyl (ethenoxy)4 ammonium bromide, N-alkyl (C12.I3)dimethylbenzyl ammonium chloride, N-alkyl (C14-ι8)dimethyl-benzyl ammonium chloride, N-tetradecylidmethylbenzyl ammonium chloride monohydrate, dimethyl didecyl ammonium chloride, N-alkyl and (C12.14) dimethyl 1- napthyhnethyl ammonium chloride, trimethylammonium halide, alkyl-trimethylammonium salts, dialkyl-dimethylammonium salts, lauryl trimethyl ammonium chloride, ethoxylated alkyamidoalkyldialkylammonium salt, an ethoxylated trialkyl ammonium salt, dialkylbenzene diaUcylammonium chloride, N-didecyldimethyl ammonium chloride, N- tetradecyldimethylbenzyl ammonium, chloride monohydrate, N-alkyl(C,2_]4) dimethyl 1- naphthylmethyl ammonium chloride, dodecyldimethylbenzyl ammonium chloride, dialkyl benzenealkyl ammomum chloride, lauryl trimethyl ammonium chloride, alkylbenzyl methyl ammonium chloride, alkyl benzyl dimethyl ammomum bromide, C12 trimethyl ammomum bromides, C1S trimethyl ammonium bromides, C17 trimethyl ammonium bromides, dodecylbenzyl triethyl ammonium chloride, poly-diallyldimethylammomum chloride (DADMAC), dimethyl ammomum chlorides, alkyldimethylammomum halogenides, tricetyl methyl ammonium chloride, decyltrimethylammonium bromide, dodecyltriethylammonium bromide, tetradecyltrimethylammonium bromide, methyl trioctylammonium chloride, POLYQUAT 10™, tetrabutylammonium bromide, benzyl trimethylammonium bromide, choline esters, benzalkonium chloride, stearalkonium chloride compounds, cetyl pyridinium bromide, cetyl pyridinium chloride, halide salts of quaternized polyoxyethylalkylamines, MΓRAPOL™, ALKAQUAT™, alkyl pyridinium salts; amines, amine salts, amine oxides, imide azolinium salts, protonated quaternary acrylamides, methylated quaternary polymers, and cationic guar.
30. The composition of claim 27 or 29, wherein the composition is bioadhesive.
31. The composition of any one of claims 1-30, wherein the Tmax of the active agent, when assayed in the plasma of a mammalian subject following administration, is less than the Tmax for a non-nanoparticulate form of the same active agent, administered at the same dosage.
32. The composition of claim 31 , wherein the Tmax is selected from the group consisting of not greater than about 90%o, not greater than about 80%, not greater than about 70%), not greater than about 60%, not greater than about 50%, not greater than about 30%o, not greater than about 25%>, not greater than about 20%>, not greater than about 15%, and not greater than about 10% of the Tmax, exhibited by a non-nanoparticulate formulation of the same active agent, administered at the same dosage.
33. The composition of any one of claims 1-32, wherein the Cmax of the active agent, when assayed in the plasma of a mammalian subject following administration, is greater than the Cmax for a non-nanoparticulate form of the same active agent, admimstered at the same dosage.
34. The composition of claim 33, wherein the Cmax is selected from the group consisting of at least about 10%>, at least about 20%>, at least about 30%, at least about 40%, at least about 50%o, at least about 60%, at least about 70%, at least about 80%, at least about 90%), and at least about 100% greater than the Cmax exhibited by a non-nanoparticulate formulation of the same active agent, administered at the same dosage.
35. The composition of any one of claims 1-34, wherein the AUC of the active agent, when assayed in the plasma of a mammalian subject following administration, is greater than the AUC for a conventional, non-nanoparticulate form of the same active agent, admimstered at the same dosage.
36. The composition of claim 35, wherein the AUC is selected from the group consistmg of at least about 10%, at least about 20%, at least about 30%,, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%,, and at least about 100%) greater than the AUC exhibited by a non-nanoparticulate formulation of the same active agent, administered at the same dosage.
37. The composition of any one of claims 1-36 which does not produce significantly different absorption levels when administered under fed as compared to fasting conditions.
38. The composition of claim 37, wherein the difference in absorption of the active agent composition of the invention, when administered in the fed versus the fasted state, is selected from the group consisting of less than about 100%,, less than about 90%,, less than about 80%, less than about 70%>, less than about 60%>, less than about 50%, less than about 40%), less than about 30%, less than about 25%, less than about 20%, less than about 15%,, less than about 10%, less than about 5%, and less than about 3%>.
39. The composition of any one of claims 1-38, wherein administration of the composition to a subject in a fasted state is bioequivalent to administration of the composition to a subject in a fed state, when admimstered to a human.
40. The composition of claim 39, wherein "bioequivalency" is established by a 90%, Confidence Interval of between 0.80 and 1.25 for both C-^ and AUC, when administered to a human.
41. The composition of claim 39, wherein "bioequivalency" is established by a 90% Confidence Interval of between 0.80 and 1.25 for AUC and a 90% Confidence Interval of between 0.70 to 1.43 for
Figure imgf000057_0001
when administered to a human.
42. The composition of any one of claims 1 -41 , wherein upon administration the composition redisperses such that the active agent particles have an effective average particle size selected from the group consisting of less than about 2000 nm, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.
43. The composition of any one of claims 1-42, wherein the composition redisperses in a biorelevant media such that the active agent particles have an effective average particle size selected from the group consisting of less than about 2 microns, less than about 1900 nm, less than about 1800 nm, less than about 1700 nm, less than about 1600 nm, less than about 1500 nm, less than about 1400 nm, less than about 1300 nm, less than about 1200 nm, less than about 1100 nm, less than about 1000 nm, less than about 900 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 250 nm, less than about 200 nm, less than about 150 nm, less than about 100 nm, less than about 75 nm, and less than about 50 nm.
44. A method of preparing a solid or semi-solid gelatin composition according to any one of claims 1-43, comprising: (a) combining: (i) a nanoparticulate active agent composition comprising at least one active agent and at least one surface stabilizer, wherein the active agent has an effective average particle size of less than about 2000 nm, and (ii) at least one gel forming substance which exhibits gelation sufficient to retain excess water in a solid or semi-solid form, to form a solid or semi-solid dose matrix surrounding the nanoparticulate active agent composition; and (b) forming a solid dose formulation, wherein such formation does not comprise solubilizing the at least one active agent.
45. A method of treating a subject comprising administering to the subject an effective amount of a gelatin composition according to any one of claims 1-43, wherein the composition comprises: (a) at least one active agent having an effective average particle size of less than about 2000 nm prior to inclusion in the dosage form; (b) at least one surface stabilizer; and
(c) at least one gel forming substance, which exhibits gelation sufficient to retain excess water in a solid or semi-solid state.
46. The method of claim 45, wherein the subject is fasted prior to administration.
PCT/US2003/028380 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions WO2005000265A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
DK03816299.6T DK1553927T3 (en) 2002-09-11 2003-09-11 Gel-stabilized, nanoparticle active ingredient compositions
SI200331901T SI1553927T1 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions
AT03816299T ATE487470T1 (en) 2002-09-11 2003-09-11 GEL-STABILIZED ACTIVE COMPOSITIONS IN NANOPARTICLE SIZE
EP03816299A EP1553927B9 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions
DE60334924T DE60334924D1 (en) 2002-09-11 2003-09-11 ANOTEILCHENGRÖSSE
JP2005503259A JP4878839B2 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticle active substance composition
AU2003304237A AU2003304237A1 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions
CA2498207A CA2498207C (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40958702P 2002-09-11 2002-09-11
US60/409,587 2002-09-11

Publications (2)

Publication Number Publication Date
WO2005000265A2 true WO2005000265A2 (en) 2005-01-06
WO2005000265A3 WO2005000265A3 (en) 2005-05-12

Family

ID=33551184

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/028380 WO2005000265A2 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions

Country Status (13)

Country Link
US (1) US7713551B2 (en)
EP (1) EP1553927B9 (en)
JP (1) JP4878839B2 (en)
AT (1) ATE487470T1 (en)
AU (1) AU2003304237A1 (en)
CA (1) CA2498207C (en)
CY (1) CY1110949T1 (en)
DE (1) DE60334924D1 (en)
DK (1) DK1553927T3 (en)
ES (1) ES2355723T3 (en)
PT (1) PT1553927E (en)
SI (1) SI1553927T1 (en)
WO (1) WO2005000265A2 (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021367A1 (en) * 2004-08-20 2006-03-02 Gelita Ag Nanoparticles and method for the production thereof
WO2006060698A1 (en) * 2004-12-03 2006-06-08 Elan Pharma International Ltd. Nanoparticulate benzothiophene formulations
WO2007066147A1 (en) * 2005-12-07 2007-06-14 Pharmakodex Ltd Topical compositions for paediatric use
JP2009508859A (en) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド Nanoparticulate aripiprazole formulation
EP2540287A1 (en) 2011-07-01 2013-01-02 FutureChemistry Continuous flow production of gelatin nanoparticles
FR2999086A1 (en) * 2012-12-10 2014-06-13 Ethypharm Sa ORAL AND / OR ORAL COMPOSITION IN FINE FILM FORM OF A LOW SOLUBLE ACTIVE INGREDIENT, PROCESS FOR PREPARING THE SAME AND USE THEREOF
CN105981748A (en) * 2015-05-07 2016-10-05 博约生物科技(苏州)有限公司 Method for extracting effective ingredients of natural bactericidal agent
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US10966926B2 (en) 2010-04-14 2021-04-06 Vitux Group As Oral pharmaceutical dispersion compositions
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US11510877B2 (en) 2017-10-10 2022-11-29 Capsugel Belgium Nv Gelling multiparticulates
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
NZ511442A (en) * 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
EP1471887B1 (en) * 2002-02-04 2010-04-21 Elan Pharma International Ltd. Nanoparticulate compositions having lysozyme as a surface stabilizer
CA2502825A1 (en) * 2002-10-22 2004-05-06 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
JP2006509502A (en) * 2002-12-11 2006-03-23 フェローサン アクティーゼルスカブ Gelatin-based material as a swab
ATE388698T1 (en) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc COMPOSITIONS TO AFFECT WEIGHT LOSS
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007519450A (en) * 2004-01-30 2007-07-19 フェロサン アー／エス Hemostasis sprays and compositions
JP2007536259A (en) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド Particles for active drug delivery
AU2005262070B2 (en) * 2004-07-09 2011-01-27 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
MX2007009915A (en) * 2005-02-15 2007-11-06 Elan Pharma Int Ltd Aerosol and injectable formulations of nanoparticulate benzodiazepine.
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
US20070003628A1 (en) * 2005-05-10 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel formulations
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
KR20080017065A (en) * 2005-06-03 2008-02-25 엘란 파마 인터내셔널 리미티드 Nanoparticulate acetaminophen formulations
CA2610448A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
JP2009517485A (en) 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド Nanoparticulate and controlled release compositions containing cefditoren
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
AU2006259606A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
JP2008543862A (en) * 2005-06-15 2008-12-04 エラン ファーマ インターナショナル リミテッド Nanoparticulate azelnidipine formulation
US9119899B2 (en) * 2006-01-18 2015-09-01 Cormatrix Cardiovascular, Inc. Method and system for treatment of cardiovascular disorders
EP1937217A2 (en) * 2005-09-13 2008-07-02 Elan Pharma International Limited Nanoparticulate tadalafil formulations
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
WO2007062228A1 (en) * 2005-11-28 2007-05-31 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US7858609B2 (en) * 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
ES2684821T3 (en) 2005-12-29 2018-10-04 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US8287929B2 (en) * 2006-05-26 2012-10-16 Cruz Serrano Jose Antonio Protein gelatinous food and its manufacture process
BRPI0712130A2 (en) * 2006-05-30 2012-01-17 Elan Pharma Int Ltd nanoparticulate posaconazole formulations
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
BRPI0713447A2 (en) * 2006-06-23 2012-03-13 Elan Pharma International Limited solid oral dosage form composition, and, method for treating pain
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
KR100809903B1 (en) 2006-09-05 2008-03-06 주식회사유한양행 Stabilized clopidogrel-containing particles, processes for preparing the same, and pharmaceutical compositions comprising the same
KR20180066272A (en) 2006-11-09 2018-06-18 오렉시젠 세러퓨틱스 인크. Unit dosage packages
RU2452471C2 (en) 2006-11-09 2012-06-10 Ориксиджен Терапьютикс, Инк. [Сша/Сша] Layered pharmaceutical compositions
BRPI0717721A2 (en) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "COMPLEX DRUG PARTICLES, PHARMACEUTICAL COMPOSITION, USE OF A PHARMACEUTICAL COMPOSITION, COMPLEX DRUG PARTICLES STABILIZED IN THE SIZE, METHOD FOR THE PREPARATION OF STABILIZED DRUG PARTICLES, EMOTIONAL COMPOSITION IN PHARMACEUTICAL, PHARMACEUTICAL UNDERSTANDING
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EP2137182A1 (en) * 2007-03-16 2009-12-30 Elan Pharma International Limited Combination of a narcotic and a non-narcotic analgesic
KR100761041B1 (en) 2007-03-22 2007-10-04 현대약품 주식회사 Pharmaceutical composition comprising acid-labile benzimidazole compound
KR100761040B1 (en) 2007-03-22 2007-10-04 현대약품 주식회사 Pharmaceutical composition comprising acid-labile benzimidazole compound
CA2688736C (en) * 2007-04-10 2017-07-04 Saint Simeon Lda Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
JP4941977B2 (en) * 2007-04-11 2012-05-30 大蔵製薬株式会社 Oral jelly-like pharmaceutical composition of benzisoxazole derivative
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PT103765A (en) * 2007-06-20 2008-12-22 Inst Superior Tecnico SYNTHESIS AND APPLICATION OF A FAMILY OF NEW MATERIALS RESULTING FROM CROSSING BETWEEN GELATINE AND ORGANIC SALTS
EP2227212A1 (en) * 2007-12-07 2010-09-15 BioCure, Inc. Bone substitute
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
CA2716872C (en) * 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US8389012B2 (en) * 2008-03-07 2013-03-05 The Corporation Of Mercer University Gellan-gum nanoparticles and methods of making and using the same
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
WO2010133961A1 (en) 2009-05-22 2010-11-25 Inventia Healthcare Private Limited Extended release compositions of cyclobenzaprine
EP2435027B1 (en) 2009-05-27 2016-10-05 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
JP5947717B2 (en) * 2009-06-19 2016-07-06 ナノフォーム ハンガリー リミテッド Nanostructured sildenafil base, pharmaceutically acceptable salts and co-crystals thereof, compositions thereof, methods of preparation thereof, and pharmaceutical compositions containing them
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
CA2779681A1 (en) 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
WO2011085331A1 (en) * 2010-01-11 2011-07-14 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
JP2013519673A (en) 2010-02-10 2013-05-30 レクシコン ファーマシューティカルズ インコーポレイテッド Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
KR20140007798A (en) 2010-09-13 2014-01-20 베브-알엑스, 인코포레이티드 Aqueous drug delivery system comprising off - flavor masking agent
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
JP6146814B2 (en) * 2011-02-11 2017-06-14 エッジ セラピュティックス インコーポレイテッド Compositions and methods for improving human prognosis of subarachnoid hemorrhage
AU2012240131B2 (en) 2011-04-05 2017-07-20 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CN107875117A (en) * 2011-04-11 2018-04-06 维特斯集团 Oral drugs dispersive composition
WO2013035423A1 (en) * 2011-09-09 2013-03-14 東洋カプセル株式会社 Pharmaceutical composition containing candesartan cilexetil
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
KR20210012056A (en) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
KR20160081646A (en) * 2014-12-31 2016-07-08 건일제약 주식회사 An oral composite tablet containing melatonin and sertraline
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN109715151A (en) 2016-08-11 2019-05-03 奥维德医疗公司 For treating the method and composition of epilepsy sexual disorder
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
MX2022006014A (en) 2019-12-06 2022-06-22 Marinus Pharmaceuticals Inc Ganaxolone for use in treating tuberous sclerosis complex.
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4122453A1 (en) * 2021-07-22 2023-01-25 Universität Heidelberg Thermoreversible gelatin matrix for stability enhancement and ready-to-use liquid application of nanoparticles and colloidal drugs

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5318767A (en) 1991-01-25 1994-06-07 Sterling Winthrop Inc. X-ray contrast compositions useful in medical imaging
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5328404A (en) 1993-03-29 1994-07-12 Sterling Winthrop Inc. Method of x-ray imaging using iodinated aromatic propanedioates
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5518187A (en) 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5741522A (en) 1991-07-05 1998-04-21 University Of Rochester Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods
US5862999A (en) 1994-05-25 1999-01-26 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5932245A (en) 1991-12-05 1999-08-03 Alfatec Pharma Gmbh Gelatin or collagen hydrolysate containing drug formulation that provides for immediate release of nanoparticle drug compounds
US6066332A (en) 1991-12-05 2000-05-23 Alfatec-Pharma Gmbh Immediate-effect ibuprofen-containing medicament and its use
US6217902B1 (en) 1995-06-09 2001-04-17 R. P. Scheier Company Soft gelatin capsules containing particulate material

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003999A (en) * 1972-10-25 1977-01-18 A. H. Robins Company, Incorporated Aspirin-tea coprecipitates for treating inflammation
US4486412A (en) 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
US4882157A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for anti-cholesterolemics
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4837255A (en) * 1987-03-10 1989-06-06 Ciba-Geigy Corporation Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
AU4990696A (en) 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
WO1997011203A1 (en) * 1995-09-19 1997-03-27 Alcan International Limited Precipitation-hardened aluminum alloys for automotive structural applications
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
NL1009107C2 (en) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Extrusion device for forming multi layer gelatine films used to form soft gel capsules - contains two height adjustable gate valves covering nozzle opening to control thickness of the individual extruded gelatine film layers
US6432442B1 (en) * 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6258380B1 (en) 1999-03-05 2001-07-10 Banner Pharmacaps, Inc. Chewable soft capsule
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
ATE271922T1 (en) 1999-06-01 2004-08-15 Elan Pharma Int Ltd SMALL MILL AND METHOD THEREOF
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
EP1313564B1 (en) 2000-04-26 2009-12-30 Elan Pharma International Limited Apparatus for sanitary wet milling
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6685961B1 (en) 2000-10-24 2004-02-03 Banner Pharmacaps, Inc. Colored gelatin-based formulations and method
WO2002098565A1 (en) 2001-06-05 2002-12-12 Elan Pharma International Limited System and method for milling materials
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
DE10244504A1 (en) 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Quick-release dosage form with poorly soluble active ingredient
US20060088590A1 (en) 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4997454A (en) 1984-05-21 1991-03-05 The University Of Rochester Method for making uniformly-sized particles from insoluble compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US5318767A (en) 1991-01-25 1994-06-07 Sterling Winthrop Inc. X-ray contrast compositions useful in medical imaging
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5776496A (en) 1991-07-05 1998-07-07 University Of Rochester Ultrasmall porous particles for enhancing ultrasound back scatter
US5741522A (en) 1991-07-05 1998-04-21 University Of Rochester Ultrasmall, non-aggregated porous particles of uniform size for entrapping gas bubbles within and methods
US6066332A (en) 1991-12-05 2000-05-23 Alfatec-Pharma Gmbh Immediate-effect ibuprofen-containing medicament and its use
US5932245A (en) 1991-12-05 1999-08-03 Alfatec Pharma Gmbh Gelatin or collagen hydrolysate containing drug formulation that provides for immediate release of nanoparticle drug compounds
US5518187A (en) 1992-11-25 1996-05-21 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5328404A (en) 1993-03-29 1994-07-12 Sterling Winthrop Inc. Method of x-ray imaging using iodinated aromatic propanedioates
US5862999A (en) 1994-05-25 1999-01-26 Nano Systems L.L.C. Method of grinding pharmaceutical substances
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6217902B1 (en) 1995-06-09 2001-04-17 R. P. Scheier Company Soft gelatin capsules containing particulate material

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Cationic Surfactants: Physical Chemistry", 1991, MARCEL DEKKER
J. CROSS; E. SINGER: "Cationic Surfactants: Analytical and Biological Evaluation", 1994, MARCEL DEKKER
J. RICHMOND: "Cationic Surfactants: Organic Chemistry", 1990, MARCEL DEKKER

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006021367A1 (en) * 2004-08-20 2006-03-02 Gelita Ag Nanoparticles and method for the production thereof
WO2006060698A1 (en) * 2004-12-03 2006-06-08 Elan Pharma International Ltd. Nanoparticulate benzothiophene formulations
AU2005311731B2 (en) * 2004-12-03 2010-12-23 Elan Pharma International Ltd. Nanoparticulate benzothiophene formulations
JP2009508859A (en) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド Nanoparticulate aripiprazole formulation
JP2013136621A (en) * 2005-09-15 2013-07-11 Elan Pharma Internatl Ltd Nanoparticle aripiprazole formulation
WO2007066147A1 (en) * 2005-12-07 2007-06-14 Pharmakodex Ltd Topical compositions for paediatric use
US10966926B2 (en) 2010-04-14 2021-04-06 Vitux Group As Oral pharmaceutical dispersion compositions
US9289499B2 (en) 2011-07-01 2016-03-22 Futurechemistry Holding B.V. Continuous flow production of gelatin nanoparticles
EP2540287A1 (en) 2011-07-01 2013-01-02 FutureChemistry Continuous flow production of gelatin nanoparticles
WO2013004370A1 (en) 2011-07-01 2013-01-10 Futurechemistry Continuous flow production of gelatin nanoparticles
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
US10799611B2 (en) 2012-06-12 2020-10-13 Ferrosan Medical Devices A/S Dry haemostatic composition
US9999703B2 (en) 2012-06-12 2018-06-19 Ferrosan Medical Devices A/S Dry haemostatic composition
WO2014091134A1 (en) * 2012-12-10 2014-06-19 Ethypharm Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
US9603797B2 (en) 2012-12-10 2017-03-28 Ethypharm Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
AU2013357113B2 (en) * 2012-12-10 2018-07-19 Ethypharm Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
FR2999086A1 (en) * 2012-12-10 2014-06-13 Ethypharm Sa ORAL AND / OR ORAL COMPOSITION IN FINE FILM FORM OF A LOW SOLUBLE ACTIVE INGREDIENT, PROCESS FOR PREPARING THE SAME AND USE THEREOF
CN104902873A (en) * 2012-12-10 2015-09-09 爱的发公司 Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same
US9724078B2 (en) 2013-06-21 2017-08-08 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10595837B2 (en) 2013-06-21 2020-03-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
US10111980B2 (en) 2013-12-11 2018-10-30 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11103616B2 (en) 2013-12-11 2021-08-31 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
US11046818B2 (en) 2014-10-13 2021-06-29 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
US10653837B2 (en) 2014-12-24 2020-05-19 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
CN105981748A (en) * 2015-05-07 2016-10-05 博约生物科技(苏州)有限公司 Method for extracting effective ingredients of natural bactericidal agent
CN105981748B (en) * 2015-05-07 2018-12-04 博约生物科技(苏州)有限公司 A method of extracting natural bacteriostatic agent effective component
US10918796B2 (en) 2015-07-03 2021-02-16 Ferrosan Medical Devices A/S Syringe for mixing two components and for retaining a vacuum in a storage condition
US11510877B2 (en) 2017-10-10 2022-11-29 Capsugel Belgium Nv Gelling multiparticulates
US11801324B2 (en) 2018-05-09 2023-10-31 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition

Also Published As

Publication number Publication date
WO2005000265A3 (en) 2005-05-12
ATE487470T1 (en) 2010-11-15
EP1553927B9 (en) 2011-09-21
ES2355723T3 (en) 2011-03-30
EP1553927A2 (en) 2005-07-20
US7713551B2 (en) 2010-05-11
PT1553927E (en) 2010-11-22
AU2003304237A8 (en) 2005-01-13
CY1110949T1 (en) 2015-06-10
CA2498207A1 (en) 2005-01-06
CA2498207C (en) 2012-03-13
JP2006514688A (en) 2006-05-11
DK1553927T3 (en) 2011-01-31
SI1553927T1 (en) 2010-12-31
JP4878839B2 (en) 2012-02-15
EP1553927B1 (en) 2010-11-10
US20050031691A1 (en) 2005-02-10
DE60334924D1 (en) 2010-12-23
AU2003304237A1 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
US7713551B2 (en) Gel stabilized nanoparticulate active agent compositions
US8236352B2 (en) Glipizide compositions
US9101549B2 (en) Nanoparticulate megestrol formulations
JP4776233B2 (en) Fast disintegrating solid formulation that is resistant to abrasion and contains pullulan
US6908626B2 (en) Compositions having a combination of immediate release and controlled release characteristics
US20070098805A1 (en) Methods of making and using novel griseofulvin compositions
US20040115134A1 (en) Novel nifedipine compositions
US20030215502A1 (en) Fast dissolving dosage forms having reduced friability
CA2534924A1 (en) Novel metaxalone compositions
US20090104273A1 (en) Novel nifedipine compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2498207

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005503259

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003816299

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003816299

Country of ref document: EP